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         Ipomoeassin F is a flagship congener of a resin glycoside family that inhibits growth of many 
tumor cell lines with only single-digital nanomolar IC50 values. However, biological and 
pharmacological mechanisms of ipomoeassin F have been undefined. To facilitate exploration of 
the biological and pharmacological properties, we performed sophisticate SAR (Structure–activity 
relationship) studies of ipomoeassin F to understand its pharmacophore and structure properties so 
that we can design favorable probes for further biological investigation. By applying appropriate 
deviates that possess fluorescent groups and similar bio-activity, the target protein was found to 
be localized in endoplasmic reticulum (ER). Through biotin affinity pull down and proteomics 
studies, the target protein Sec61α (protein transport protein Sec61 subunit alpha isoform 1) was 
successfully isolated and confirmed. The isolated protein validation by Western blot provides 
convincing evidence to support the conclusion that Sec61α is the primary molecular target. 
Subsequently, the binding mode between ipomoeassin F and Sec61α was proved to be non-
covalent or reversible covalent binding with the help of reverse/delayed competition. Based on 
competition result between ipomoeassin F and the derivatives with different activities, future 
applications of those derivatives to search for detect Sec61α-specific bio-active compounds by 
high throughput screening (HTS) are proposed. As a novel plant-derived carbohydrate-based 
macrocyclic molecule, ipomoeassin F was proved to have an exclusive mode of action. The 
successfully identification of its target protein Sec61α provides a new molecular tool to further 
understand the Sec61α biological properties and its potential to be a new therapeutic target for 
drug discovery. Most importantly, the information about this distinct mode of action would lead 







© 2019 by Zhijian Hu 














Acknowledgements          
         I thank Dr. Sun-OK Lee, Dr. T.M.S. Kumar and Dr. Gisela F. Erf for being my committee 
member, treating each committee meeting as their special class to teach me more scientific 
thinking and academic management.     
         I gratitude for the generous guidance and teaching from Dr. Yuchun Du and Mrs. Jianhong 
Zhou all through my research. with their kindly help, I not only learned lots of fancy techniques 
but also enjoyed the charm of biologic research, which would benefit my whole life.  
         I thank my advisor, Dr. Wei Shi, for accepting me into the research group, helping me adjust 
to the academic life, mentoring me to be a creative biologist step by step, and patiently guiding me 
to overcome all kinds of obstacles. His is more than a thoughtful advisor but also a reliable friend 
who would always stand by me whenever I needed help.  
         I thank all the members of the Shi group for long time support, thank Dr. Gunaghui Zong for 
helping me adjust to the life in the first couple of weeks when I came here and support me in the 
chemistry lab.  
         I thank Dr. Hazim Al-jewari and Dr. Xianwei Sun for teaching me basic biological and 
chemical techniques. Thank Dr. Lucas Whisenhunt, Dr. Eric Barber and Dr. Mugunthan 
Govindarajan for their work and assistance in the chemistry lab.  
         Most importantly, I thank God for putting so many awesome people in my life. And we know 
that in all things God works for the good of those who love him, who have been called according 




         This work is dedicated to my family for the unconditional love, tolerance, and guidance 
since the beginning of my life. Thanks for their support and encourage whenever I was down. I 
appreciate my wife Ping Zhang for her unconditional support and irreplaceable help during this 
journey. Thanks for being the most important person in my life and teaching me to always be 



















Table of Contents 
CHAPTER 1. BACKGROUND AND INTRODUCTION ........................................................ 1 
1.1. Cancer Epidemiology .......................................................................................................... 1 
1.1.1. Cancer ........................................................................................................................... 1 
1.1.2 Breast Cancer ................................................................................................................. 2 
1.2. Nature Product Ipomoeassins F ........................................................................................... 4 
1.2.1. Nature product .............................................................................................................. 4 
1.2.2. Resin Glycosides and Ipomoeassin family ................................................................... 5 
1.2.3. Target identification ...................................................................................................... 7 
1.3. Statement of the Problem ..................................................................................................... 9 
1.4. References .......................................................................................................................... 11 
CHAPTER 2. SAR STUDY AND PROBE EXPLORATION ................................................ 15 
2.1. SAR study .......................................................................................................................... 15 
2.1.1. Structure-activity information from ipomoeassin family members ............................ 15 
2.1.2 Structure-activity information from characteristic structure modification .................. 16 
2.1.3. Structure-activity information from cinnamate and tiglate modification ................... 18 
2.1.4. Structure-activity information from hydrophilic moieties modification .................... 21 
2.1.5. Structure-activity information from aglycone modification ....................................... 22 
2.1.5.1. Impact of stereogenic center C-11 on ipomoeassin F bioactivity. ....................... 22 
2.1.5.2. Impact of open-chain aglycone on ipomoeassin F bioactivity. ............................ 23 
 
 
2.1.5.3. Impact of cyclic structure size on ipomoeassin F bioactivity. ............................. 25 
2.1.6. Structure-activity information from fucose modification ........................................... 26 
2.1.7. Summarize of structure-activity relationship study .................................................... 27 
2.2. Probe Design and Selection ............................................................................................... 29 
2.2.1. Probes for stepwise target protein identification ........................................................ 30 
2.2.2. Probes for ABPP by fluorophore reporter .................................................................. 32 
2.2.3. Probes for ABPP by affinity tag reporter .................................................................... 34 
2.2.4. Summary of Probes design and selection. .................................................................. 36 
2.3. References .......................................................................................................................... 37 
CHAPTER 3. IPMOEASSIN F TARGET PROTEIN IDENTIFICATION AND 
VALIDATION............................................................................................................................. 39 
3.1. Abstract .............................................................................................................................. 39 
3.2. Introduction ........................................................................................................................ 39 
3.3. Results and Discussion ................................................................................................... 42 
3.3.1. Proteomics Evaluations of Chemical Probes derived from Ipomoeassin F. ............... 42 
3.3.2. Cell Imaging Studies. .................................................................................................. 49 
3.3.3. Pulldown from ER Microsomes. ................................................................................. 50 
3.3.4. Pulldown from ER Microsomes. ................................................................................. 51 
3.3.5. ipomoeassin F and Sec61α interaction mode exploration........................................... 51 
3.4. Conclusions .................................................................................................................... 54 
 
 
3.5. Supporting Information .................................................................................................. 55 
3.5.1. Cytotoxicity Assay ...................................................................................................... 55 
3.5.1.1. Cell Culture .......................................................................................................... 55 
3.5.1.2. MTT Cytotoxicity Assay ..................................................................................... 55 
3.5.1.3. AlamarBlue Cytotoxicity Assay .......................................................................... 56 
3.5.2. Stepwise Activity Based Protein Profiling ................................................................. 56 
3.5.3. Biotin Affinity Pulldown ............................................................................................ 57 
3.5.3.1. Live Cell-based Pulldown .................................................................................... 57 
3.5.3.2. Cell Lysate-based Pulldown ................................................................................ 58 
3.5.3.3. ER Microsome-based Pulldown .......................................................................... 59 
3.5.4. Mass Spectrometry (MS) Analysis and MS Data Processing ..................................... 59 
3.5.5. Cell Imaging ................................................................................................................ 60 
3.5.6. Figures and Tables ...................................................................................................... 62 
3.5.6.1. Cell Cytotoxicity Assay ....................................................................................... 62 
3.5.6.2. Stepwise Activity Based Protein Profiling .......................................................... 63 
3.5.6.3. Biotin Affinity Pulldown ..................................................................................... 64 
3.5.6.4. Cell Imaging......................................................................................................... 66 
3.5.6.5. Pulldown in ER Microsomes. .............................................................................. 67 
References ................................................................................................................................. 84 
 
 
CHAPTER 4. FUTURE PROJECT: APPLICATION FOR HIGH-THROUGHPUT 
SCREENING ............................................................................................................................... 87 
4.1. Fluorescent probe based HTS study ............................................................................... 88 
4.1.1. Mechanism for fluorescent probe based HTS research .............................................. 88 
4.1.2. Optimal work concentration exploration for cell imaging .......................................... 90 
4.1.3. Optimal treatment time exploration for cell imaging.................................................. 92 
4.1.4. Optimal fold competition of ipomoeassin F for cell imaging ..................................... 95 
4.1.5. Optimal competition time of ipomoeassin F for cell imaging .................................... 97 
4.1.6. Procedure design for fluorescent probe based HTS research ..................................... 99 
4.1.7. Result interpretation .................................................................................................. 100 
4.2. Biotin probe based HTS study ..................................................................................... 101 
4.2.1. Mechanism for biotin probe based HTS research ..................................................... 101 
4.2.2. HTS work condition optimization. ........................................................................... 102 
4.2.3. Procedure design for biotin probe based HTS research ............................................ 102 
4.2.4. Result interpretation .................................................................................................. 104 
4.3. Conclusion .................................................................................................................... 104 
4.4. References .................................................................................................................... 106 
SUMMARY AND CONCLUSIONS……………………………….….………………...…...107 





List of Figures 
CHAPTER 1. BACKGROUND AND INTRODUCTION ........................................................ 1 
Figure 1.1 Estimated New Cancer Cases and Deaths by Sex, United States, 2019. ...................... 1 
Figure 1.2 Trends in Incidence Rates for Selected Cancers by Sex, United States, 1975 to 2015..
......................................................................................................................................................... 3 
Figure 1.3. Target protein identification by affinity purification. .................................................. 8 
CHAPTER 2. SAR STUDY AND PROBE EXPLORATION ................................................ 15 
Figure2. 1. Structures of ipomoeassin F and its analogues 2.1-2.4.............................................. 17 
Figure2. 2. Structure of ipomoeassin F analogues 2.5-2.8. .......................................................... 19 
Figure2. 3. Structure of ipomoeassin F analogues 2.8-2.10. ........................................................ 20 
Figure2. 4. Viability curves of ipomoeassin F and analogues 2.8, 2.9, 2.10 in breast cancer cell 
lines ............................................................................................................................................... 21 
Figure2. 5. Structures of ipomoeassin F analogues 2.11-2.12. .................................................... 22 
Figure2. 6. Structures of ipomoeassin F and its C-11R epimer 2.13. .......................................... 23 
Figure2. 7. Structures of ipomoeassin F analogues 2.14 and 2.15. .............................................. 24 
Figure2. 8. Structures of ipomoeassin F and its analogues 2.16 and 2.17. .................................. 25 
Figure2. 9. Structures of ipomoeassin F analogues 2.18 and 2.19. .............................................. 26 
Figure2. 10. Viability curves of ipomoeassin F and analogues 2.18 and 2.19 in breast cancer cell 
lines ............................................................................................................................................... 27 
Figure2. 11. Cytotoxicity loss by pharmacophore editing. .......................................................... 28 
Figure2. 12. The four pillars of cell-based target validation using chemical probes. .................. 30 
Figure2. 13. Structure and cytotoxicity of ipomoeassin F analogues 2.20 and 2.21.. ................. 31 
Figure2. 14. Diagram of stepwise target protein identification. .................................................. 32 
 
 
Figure2. 15. Structure of ipomoeassin F analogues 2.22-2.28. .................................................... 33 
Figure2. 16. Structures of ipomoeassin F analogues 2.29 - 2.33. ................................................ 35 
CHAPTER 3. IPMOEASSIN F TARGET PROTEIN IDENTIFICATION AND 
VALIDATION............................................................................................................................. 39 
Figure 3. 1. Structures of ipomoeassins A, D, and F. .................................................................. 41 
Figure 3. 2. Structure of ipomoeassin F analogues 3.1-3.3. ......................................................... 42 
Figure 3. 3. Affinity pulldown using probe 3.3. .......................................................................... 45 
Figure 3. 4. Structure and cytotoxicity of ipomoeassin F analogues 3.4-3.5.. ............................. 46 
Figure 3. 5. Affinity pulldown using probe 3.3, 3.4 and 3.5.. ...................................................... 47 
Figure 3. 6. Structures of ipomoeassins F analogues 3.1 and 3.6. ............................................... 48 
Figure 3. 7. Structures of fluorescent derivative 3.7 . .................................................................. 49 
Figure 3. 8. Cell imaging studies with fluorescent probe 3.7 in MDA-MB-231 cells.. ............... 50 
Figure 3. 9. Traditional completion and reverse competition between ipomoeassin F and 
analogue 3.3:. ................................................................................................................................ 53 
Figure S 1. Cytotoxicity in MDA-MB-231: Cell viability curves of analogues 3.1, 3.2, 3.3, 3.7 
and ipomoeassin F......................................................................................................................... 62 
Figure S 2. Click reaction performed after incubating cells with competitor and its 
corresponding alkyne probe.. ........................................................................................................ 63 
Figure S 3. Biotin affinity pulldown with probes 3.2 and 3.3... ................................................... 64 
Figure S 4. Biotin affinity pulldown with probe 3.3 or 3.5 in the presence of the competitor 
ipomoeassin F or 3.6.. ................................................................................................................... 65 
Figure S 5. Live cell imaging-based competition experiments. ................................................... 66 
Figure S 6. Biotin affinity pulldown with probe 3.3 in ER microsomes.. ................................... 67 
 
 
CHAPTER 4. FUTURE PROJECT: APPLICATION FOR HIGH-THROUGHPUT 
SCREENING ............................................................................................................................... 87 
Figure 4. 1. Ipomoeassin F analogues 4.1, 4.2. ............................................................................ 88 
Figure 4. 2. Live cell imaging-based competition experiments.. ................................................. 89 
Figure 4. 3. Live cell imaging from 4.1 incubation at different concentration.. .......................... 92 
Figure 4. 4. Live cell imaging from 4.1 100nM treatment at different time incubation. ............. 95 
Figure 4. 5. Live cell confocal fluorescent microscopy imaging from 1h 4.1 100nM treatment 
and 30min ipomoeassin F competition at different competition fold difference:. ........................ 97 
Figure 4. 6. Live cell imaging from 1h 4.1 100nM treatment and 100-fold ipomoeassin F 
competition at different competition time..................................................................................... 99 
Figure 4. 7. Structure of ipomoeassin F analogues 4.3. ............................................................. 101 






List of Tables 
CHAPTER 1. BACKGROUND AND INTRODUCTION ........................................................ 1 
Table 1.1. Structures and IC50 Values of Ipomoeassin A–F. ......................................................... 6 
CHAPTER 2. SAR STUDY AND PROBE EXPLORATION ................................................ 15 
Table 2. 1. Structures and IC50 Values of Ipomoeassin A–F. ...................................................... 16 
Table 2. 2. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.1-2.4 ........................ 18 
Table 2. 3. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.5-2.8 ........................ 19 
Table 2. 4. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.11-2.12 .................... 22 
Table 2. 5. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its epimer 2.13 ................................. 23 
Table 2. 6. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.14-2.15 .................... 24 
Table 2. 7. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its analogues 2.16-2.17 .................... 26 
Table 2. 8. Cytotoxicity (IC50, nM) of Ipomoeassin F and its Probes 2.22-2.28 ......................... 34 
Table 2. 9. Cytotoxicity (IC50, nM) of Ipomoeassin F and its Probes 2.29-2.33 ......................... 36 
CHAPTER 3. IPMOEASSIN F TARGET PROTEIN IDENTIFICATION AND 
VALIDATION………………………………………………………………………………….39 
Table 3. 1. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its Probes 3.1-3.7 ............................. 43 






IC50: Half Maximal Inhibitory Concentration 
SAR: Structure–Activity Relationship 
ER: Endoplasmic Reticulum  
HTS: High Throughput Screening 
TNBC: Triple-negative breast cancer  
PR: Progesterone Receptor  
HER-2: Human Epidermal Growth Factor Receptor 2 
FDA: U.S. Food and Drug Administration 
NCEs: New Chemical Entities  
NCI: National Cancer Institution  
MOA: Mechanism of Action  
MS: Mass Spectrometry  
ABPP: Active-Based Protein Profiling  
Glcp: Glucose 
Fucp: Fructose  
CuAAC: Copper-catalyzed Alkyne-Azide Coupling 
FBS: Fetal Bovine Serum  
DMSO: Dimethyl Sulfoxide 
DDM: n-Dodecyl-ß-D-Maltoside 
FDR: False Discovery Rate 




List of Published Papers 
Portion of Chapter 3 is from the paper listed below  
• Zong G.; * Hu Z.; * O’Keefe S.; Tranter D.; Iannotti M.; Baron L.; Hall B.; Corfield K.; 
Paatero A.; Henderson M.; Roboti P.; Zhou J.; Sun X.; Govindarajan M.; Rohde J.; Blanchard 
N.; Simmonds R.; Inglese J.; Du Y.; Demangel C.; High S.; Paavilainen V.; Shi W.Q. 
Ipomoeassin F Binds Sec61α to Inhibit Protein Translocation. J Am Chem Soc. (under revision)  
*Author contributions: Zong G. and Hu Z. contributed equally to the work. 
1 
CHAPTER 1. BACKGROUND AND INTRODUCTION 
1.1. Cancer Epidemiology  
1.1.1. Cancer  
         Cancer is one of the leading public health problems worldwide, and yet the most difficult 
research area due to its intricate physiopathology. It is threatening public health as second cause 
of death in the United States,1 leading to heavy burden on the medical care system and the society.   
Figure 1.1 Estimated New Cancer Cases and Deaths by Sex, United States, 2019.1 
2 
From the data predicted, probability of being diagnosed with invasive cancer all through the 
lifetime is as high as 37.7%-39.3%.1 According to the most recent data analysis,1 there will be 
approximately 1,762,450 cancer cases diagnosed in the United States. That corresponding to more 
than 4,800 new cases will be diagnosed every day. Despite great breakthroughs in modern surgery, 
chemotherapy, radiotherapy, radiotherapy, newly established targeted therapies and 
immunotherapy significantly lessened morbidity and ameliorated survival over the past decades,2 
cancer remains one of the most dangerous killers in the United States.3 It is estimated that 606,880 
Americans will die from cancer in 2019, which is equivalent to nearly 1,700 deaths each day. From 
the literature report (Figure 1.1), there will be 268,600 new cases of breast cancer to be diagnosed, 
occupying 30% of all new woman cancers cases in 2019; and breast cancer is the second leading 
cause of death after lung cancer in woman cancer cases.   
1.1.2 Breast Cancer 
         Breast cancer is the leading cause of death among women aged 20 to 59.1 It was first 
described as a breast bulging in ancient Egyptian medical papyri.4 Over the past few decades, the 
overall cancer incidence rate in woman was relatively stable, however, breast cancer incidence 
rates increased approximately 0.3% to 1.8% from 2006 - 2015.5 This trend is clearly illustrated by 
data collected from 1975 - 2015 (Figure 2). Breast cancer survival rates vary significantly all over 
the world with an 80% 5-year survival rate in developed countries which is below 40% in 
developing countries.6   
         Breast cancer has been a worldwide critical public health problem for decades. The modern 
breast cancer treatment began in 1880s, when Halsted applied surgical approach.7 With almost 140 
years of continuous endeavor by innumerable physicians and scientists, prognosis of breast cancer 
improved significantly. However, due to the complexity of breast cancer and drug development, it 
3 
is still one of the most life threating diseases to women. It is a never-ending fight against breast 
cancer, extensive research is required to identify specific treatment and ameliorate its prognosis. 
Cancer cell lines are commonly used as the primary in vitro experimental models to understand 
cancer biology and molecular pharmacology of anticancer drugs.  
 
Figure 1.2 Trends in Incidence Rates for Selected Cancers by Sex, United States, 1975 to 2015.1 
         As a heterogeneous disease, breast cancer consists of a series of clinical and molecular 
distinct subtypes.8 Triple-negative breast cancer (TNBC) is a destructive type of breast cancer 
which lacks expression of progesterone receptor (PR), human epidermal growth factor receptor 2 
(HER-2) and estrogen receptor (ER), and the gene expression profile is often a basal-like cancer 
cell line.9 TNBC is an invasive subtype and occupies around 15% of all invasive breast cancers.10 
MDA-MB-231 cell line is a well-established human breast cancer epithelial cell line originated 
from a pleura effusion of a Caucasian female breast cancer patient.11 It is commonly used as a 
4 
TNBC cell model characterized with highly aggressive, invasive and poorly-differentiated cancer, 
endowing its great value in anti-cancer drug research.   
         MCF-7 is a commonly used breast cancer cell line established by Dr. Soule and his 
colleagues in 1973.12 It was first isolated from pleural effusion of a breast cancer metastatic case. 
MCF-7 is a luminal A molecular subtype cell line which is estrogen receptor (ER) - positive and 
progesterone receptor (PR) - positive.13,14 It is a non-invasive cell line and proved to be a suitable 
model cell line for anticancer drugs investigation.14,15 
         MCF-10 is a human breast epithelial cell line derived from s.c. mastectomy tissue from a 
patient with fibrocystic disease.16 MCF-10A is an attaching immortal cell line which originated 
from a mortal cell line MCF-10M. Electron microscopy revealed that MCF-10A has the same 
characteristics of luminal ductal cells, moreover it maintains their epithelial cell characteristics.16  
MCF-10A is considered as an important tool for investigating cell growth and carcinogenesis,16 
therefore we include this cell line as a non-cancer control to evaluate compound selectivity among 
breast cell derived cell lines.  
         In our bio-activity study, cytotoxicity of synthesized compounds was tested against the 
highly invasive breast cancer cell line MDA-MB-231, non-invasive breast cancer cell line MCF-
7 and the breast epithelial cell line MCF-10A separately. Half maximal inhibitory concentration 
(IC50) was calculated to evaluate compound potency, and the ratio between the IC50 from cancer 
cell lines versus IC50 from epithelial cell was used to estimate selectivity of each compound.  
1.2. Nature Product Ipomoeassins F 
1.2.1. Nature product 
         Nature product consists of a significant amount of families with various chemical entities 
that plays import roles in biological activities. Throughout human history, people have been 
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exploring nature for treatment of a wide spectrum of diseases regardless of their different location 
and culture. Natural products have been the most widely used source for drug development, 
especially in anti-infectives and anti-cancer studies.17-20 Over the past 75 years since the discovery 
of penicillin, more than 23,000 natural products have been identified and characterized. 21 It is 
reported that 60% of the 1500 FDA approved new chemical entities (NCEs) from 1981 to 2014 
were natural products, derivatives or mimicked natural products.17 Among the 136 approved anti-
cancer drugs, nearly 83% of the reagents were developed from natural products or were direct 
derivates.22  Within the intense competition of drug development, more and more people are 
realizing that there would be more chance of getting successful drugs from natural products rather 
than collections of synthetic compounds. 23,24 
         Nowadays numerous incurable diseases have been conquered, however cancers, a series of 
comprehensive systematic diseases, are still out of control due to the dilemma of killing cancer 
cells together with normal cells damaged while applying anti-cancer drugs. This double-edged 
sword effect originated from the lack of pinpointing effective target-oriented medicine. Therefore, 
looking for an active natural product, identifying its druggable target and designing the 
corresponding acting analogues without triggering off target effects, would be an ideal approach 
for anti-cancer development. 
1.2.2.  Resin Glycosides and Ipomoeassin family 
         Resin glycosides, which are part of glycolipids or lipo-oligosaccharides family, consist of 
complex resins (glycoresins).25 They are a group of compounds isolated from Convolvulaceae, 
and widely used as traditional medicine to perform various biological activities including purgative, 
haemolytic, laxative, antifungal, anti-bacterial and even cytotoxicity.26-30 All parts of 
Convolvulaceae, including roots, leaves, stems, bulbs and flowers have been explored and used as 
6 
medication for different diseases.26,31  A large number of glycoconjugate natural products have 
been identified to harbor anti-cancer bioactivity.32 
         The ipomoeassins, a representative of resin glycosides family, was first isolated from 
Suriname rainforest by Kingston and his colleagues in 2005 from the leaves of Ipomoea 
squamosa.33 This small class of six resin glycosides family is reported to have a range of biological 
properties including antifungal, antibacterial and cytotoxicity.27,31 Kingston et al. isolated 
ipomoeassin family A-E, and revealed their potency against an ovarian cancer cell line.33  While 
resin glycosides are reported to be potent anti-cancer reagents based on their micromolar IC50 
values against certain cancer cell lines, certain members in ipomoeassin family exhibit their anti-
cancer toxicity at nanomolar IC50 values.
34  
         NCI-60 was developed by US National Center Institute in the 1980s to maintain their own 
collection of stable, differentiated cancer cell lines.21 The panel of 60 cell lines have been 
employed to investigate the efficacy and specificity of all kinds of natural products.  As the most 
abundant in ipomoeassin family, ipomoeassin A was tested against NCI-60 cell lines and found to 
have antiproliferation activity.34 What’s more, the activity pattern was found to be unmatchable 
among known anticancer agents in National Cancer Institution (NCI) database.   





Structure  IC50 (nM) 
R1 R2 n 
 





A H Ac 1  64 77.8 500 20.2 46.1 42.6 108.9 
B H H 1  2500  400 134 396 2700 1070 
C OH Ac 1  1500 > 1000 2900 - - - - 
D OAc Ac 1  32 135 35 7.9 11.8 19.9 23.2 
E OAc H 1  4300 > 1000 3300 163 393 1633 967 
F H Ac 3  - 7.4 36 2.6 4.2 9.4 12.9 
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         Two years after the extensive study on ipomoeassin family, Kingston group isolated another 
family member ipomoeassin F, which possesses distinguished potency against multiple cancer cell 
lines.35 According to previous in vitro cytotoxicity test, it inhibits cancer cells proliferation mostly 
with IC50 value nanomolar range (Table 1.1).  The impressive cytotoxicity is even more potent 
than many clinical chemotherapeutic drugs. Interestingly, when we submitted our home made 
ipomoeassin F for test against NCI-60 cell lines, the report not only confirmed its nanomolar 
potency against couple of cell lines but also reflected its unique functional mechanism that was 
different from all existing agents in NCI databases.36 The conclusion perfectly matches previous 
research on ipomoeassin A.  
         Such high degree bioavailability of this newly discovered natural product endows its 
potential promising candidacy for efficient anti-cancer drug development. Therefore, uncovering 
the possible mode of action may pave a new road for anti-cancer development.    
1.2.3.  Target identification 
         An increasing number of natural products are well studied for potential therapeutical 
candidates, however, their further development into application is always time consuming and 
costly due to the limited understanding of the mechanism of action (MOA) and unexpected side 
effects.37  Active small molecules perform their bioactivity through various ways of interaction 
with their specific target in biological environment, As a result, identification of the pivot target 
could significantly facilitate the understanding of their MOA as well as the unwanted side effects.37 
It’s almost impossible to ignore the drug target whiling developing a mechanism-based drug.  
Revealing the target can not only predict the future clinic efficacy and safety, but also provide clue 
to understand and deal with side effects. For natural products, structural modifications through 
synthesis are a widely used approach to uncover MOA, and may lead to potential clinical drug 
8 
development. Proteins are one of the most often targets, hence development of high-accuracy 
research method will greatly improve the chance of identifying target proteins.  
 
Figure 1.3. Target protein identification by affinity purification. (A) Workflow of target protein 
identification by affinity purification and LC/MS. (B) Typical ABPP probe constitution.38 
 
         The combination of affinity chromatography and Mass spectrometry (MS) have been proved 
to be successful way of unveiling target proteins. Based on specific bioactive interactions, 
application of chemical proteomics and active-based protein profiling (ABPP) further improved 
the rapid process and accurate target protein identification, minimizing the unspecific protein 
disturbance.38-40 While working with chemical proteomics, molecular-protein interaction was 
studied through applying various synthesized probes with functional moieties. This approach often 
works together with MS to further push up greater precision and comprehensiveness than 
traditional western blot.38,41 In ABPP chemical proteomics study, active functional probes are 
design and synthesize by modification from compounds of interest. They identify the target protein 
by probing covalent or strong non-covalent binding. Usage of ABPP coupling quantitative 
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chemical proteomics has played an important role in many insightful studies and proven to be a 
powerful tool in identifying target identification.38,42   
         Probes (Figure 1.3B) designed for ABPP normally consist of three core elements: (1) reactive 
group that specifically binds the target protein; (2) a traceable tag that enables affinity purification 
(Figure 1.3A) and further image study; (3) a linker between reactive group and reporter tags. The 
linker may act as an associated target protein purification or tracing facilitator by introducing 
crosslinking or cleavable functional groups. Typical target protein identification by ABPP is 
composed of cell or cell lysate incubation, probe-target protein complex isolation and target 
protein identification.  
1.3. Statement of the Problem 
         Since Kingston group isolated and reported the ipomoeassin family in 2005, more and more 
scientists dedicate their research on exploring different properties of this potent anti-cancer agent. 
Even through certain chemical and biological characteristics have been unveiled, the 
understanding of the properties of this small family is still very limited.  
         Structure-activity relationship (SAR) study is one of the most frequently used as the first 
approach to explore the MOA of a compound. By understanding the contribution of each 
individual moiety to the bioactivity, appropriate modification could be introduced accordingly to 
introduce favorable function groups with minimum disturbance to the original bioactivity. Probes 
that maintain the biomedical properties of the compound of interest could be developed to further 
define the MOA as well as the mechanism of side effects, endowing the possibility to produce 
ideal drugs for serious diseases. From the data reported in the literature, some pieces of information 
could be obtained about certain aspects of the structure-activity character of ipomoeassin F. 
However, knowledge collected from available literature are far from sketching the contours of 
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ipomoeassin F structure - activity relationship due to the lack of appropriate analogue library to 
systematically study ipomoeassin F from all aspects.  
         As the most potent member of ipomoeassin family, ipomoeassin F has distinguished 
cytotoxic effects on different cancer cells with unknown exclusive functional mechanism, 
indicating the new compound has distinguished MOA by interacting with some novel molecular 
targets. Deciphering the action mode of ipomoeassin F could probably open a new window for 
manipulating the uncurbable cancer growth.  
         The goal of this project is to illustrate the contribution of each group of ipomoeassin F to its 
potency, and to identify the corresponding target by using applicable probes, ultimately illuminate 
the MOA of ipomoeassin F. Based on our research, we hope to apply the available discovery to 
explore potential practical applications.   
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CHAPTER 2. SAR STUDY AND PROBE EXPLORATION 
         The structures for ipomoeassin family were uncovered by spectroscopic data and chemical 
degradation.1 The ipomoeassins are composed of a (1→2)--disaccharide as a core structure, and 
hydroxylated fatty acid derivatives connecting disaccharide with different acylation patterns. The 
core structure consists of a D-Glcp and D-Fucp-derivatives, while the peripherally connects with 
cinnamate (cinn, C-4-Glcp), tiglate (tig, C-3Glcp) and aglycone. Within aglycone of ipomoeassins, 
unlike for most resin glycosides, there is an oxygenation at C-4 position,2-3 a sterogeinc center at 
C-11 position; and in some family members (ipomoeassin C-E), it contains a stereogenic center at 
C-5 position.2,4 
2.1.  Structure-Activity Relationship study 
         For newly discovered compound, structure-relationship study (SAR) study is a classical yet 
most rewarding medicinal chemistry method to understand the information of the compound 
structure. With the help SAR study, potential pharmacophores would be well illuminated and 
assigned in drug development. As a flagship congener of a resin glycoside family, ipomoeassin F 
is an ideal candidate of systematic SAR study for developing novel anti-cancer drugs. This is not 
only due to the distinguished potency of ipomoeassin F against cancer cell lines, but also because 
of the limited understanding of exclusive MOA of this underexplored natural product. In the 
systematical SAR study, all ipomoeassin F and its analogues are synthesized in our total synthesize 
lab. 
2.1.1. Structure-activity information from ipomoeassin family members  
         According to previous cytotoxicity data (Table 2.1), R1 in 4’-O site of D-fucose and R2 in C-
5 site of the fatty acid tether play a pivot role from the pharmacophoric point of view. This 
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conclusion is well elucidated by comparing the potency of ipomoeassin D and F with the rest of 
the family members. Substitution on the two moieties could even lead to two orders of magnitude 
potency change against different cancer cell lines. The available information from previous 
cytotoxicity assay (Table 2.1) suggests that additional two methylene units in fatty acid of 
ipomoeassin F result in lipophilicity increase, contributing to the potency of this amphiphilic 
glycoconjugate.5 The conclusion that overall lipophilicity is vital to potency of the ipomoeassins 
is further confirmed by comparing the IC50 value variation by the difference of OAc and OH in 
R1(ipomoeassin D vs C), as well as in R2 (ipomoeassin A vs B, ipomoeassin D vs E).  






Structure  IC50 (nM) 
R1 R2 n 
 





A H Ac 1  64 77.8 500 20.2 46.1 42.6 108.9 
B H H 1  2500  400 134 396 2700 1070 
C OH Ac 1  1500 > 1000 2900     
D OAc Ac 1  32 135 35 7.9 11.8 19.9 23.2 
E OAc H 1  4300 > 1000 3300 163 393 1633 967 
F H Ac 3   7.4 36 2.6 4.2 9.4 12.9 
 
2.1.2 Structure-activity information from characteristic structure modification  
         Some ipomoeassin family members are found to have impressive toxicity against multiple 
cancer cell lines. Variation of peripheral oxygenation and acylation pattern in ipomoeassin 
structure may trigger significant cytotoxicity fluctuation toward cancer cell lines.2 Ipomoeassins 
possesses two exclusive structure features differ from other glycosides: (1) the carbohydrate core 
structure is intensively connected to ester functionalities. (2) In the C-4 position of the fatty acid 
chain, there is a ketone group. To clarify the functionality of those unique properties, we designed 
and synthesized analogues 2.1-2.4 by removing those structure units one by one and then judging 






Figure 2. 1. Structures of ipomoeassin F and its analogues 2.1-2.4. (A) Structure of ipomoeassin 
F; (B) Structure of 2.1-2.4.  
         In the study of ipomoeassin family, the Fürstner group found that simultaneous migration 
of tiglate and cinnamate damage the bioactivity.5 The importance of these two moieties was 
further confirmed by our research data (Table 2.2).6 As we remove cinnamate (2.1) or tiglate 





         Fürstner and his colleagues also reported that removal of the C-4 ketone in the fatty acid 
chain impaired the potency.5 However, when we removed the carbonyl group in the hydrophilic 
tether, analogue 2.3 almost retained its potency with a maximum 3-fold potency loss. Compared 
to analogue 2.3, analogue 2.2 suffered relative more bioactivity loss when losing acetate group, 
further verifying the hypothesis that increasing lipophilicity could enhance the bioactivity of 
ipomoeassins. But the impact was limited at around 20-fold change, and the cytotoxicity of 
analogue 2.2 against MCF-7 was almost retained (dropped 2-fold). All the information above 
suggests the significance of influence on ipomoeassins potency in the order of cinnamoyl> 
tigloyl>>acetyl>ketone.  




MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.1 7129.2 9090.0 NDb  
2.2 131.0 86.7 297  
2.3 16.1 33.0 30.7  
2.4 6848.0 5929.0 ND  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%; b ND = not determined. 
2.1.3. Structure-activity information from cinnamate and tiglate modification   
         Since both cinnamate and tiglate are confirmed to be the most important moieties that 
contribute to ipomoeassins, we executed deep exploration within those two structure elements. 
Both of the two moieties contain an α,β-unsaturated double bond, so we concluded that the 
common structure double bond might contribute to the high cytotoxicity. Phenyl group, as a 
structural constitution element in cinnamate, may also have something to do with its functionality. 
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Figure 2. 2. Structure of ipomoeassin F analogues 2.5-2.8. 
         To verify these hypotheses, we designed and synthesized analogue 2.5 with cinnamate 
double bond reduced, 2.6 with tiglate double bond reduced, 2.7 with the cinnamate double bond 
missing and 2.8 with the phenyl group missing (Figure 2.2). The bioactivity change was evaluated 
by comparing IC50 value against breast cancer cell line MDA-MB-231 and MCF-7 respectively. 




MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.5 980 2560 NDb  
2.6 429 477 ND  
2.7 930 2890 ND  
2.8 4500 3930 ND  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%; b ND = not determined. 
         Through cytotoxicity screening, the importance of double bond in cinnamate and tiglate is 
uncovered (Table 2.3). As expected, removing any of the double bonds in cinnamate or tiglate 
result in significant potency loss. But the cytotoxicity loss of reducing or removing cinnamate 




indicating the cinnamate double bond may play more important role than tiglate double bond in 
cytotoxicity. When we removed the phenyl group by substituting cinnamate with tiglate, the 
analogue 2.8 suffered dramatically potency loss (dropped almost 700-fold), suggesting the pivot 
role of aromatic group in biological activities.    
         Since cinnamate was shown to be more important than tiglate and both of these two α,β-
unsaturated esters were critical to retain ipomoeassin F potency, we were interested to know 
whether substituting tiglate with cinnamate could increase or maintain the cytotoxicity and 
whether those two moieties were interchangeable. To answer these follow-up questions, we 
designed another two analogues 2.9 and 2.10 (Figure 2.3).  
 
Figure 2. 3. Structure of ipomoeassin F analogues 2.8-2.10. 
A.  
 




Figure 2. 4. Viability curves of ipomoeassin F and analogues 2.8, 2.9, 2.10 in breast cancer cell 
lines: (A) Cytotoxicity in MDA-MB-231 cell line; (B) Cytotoxicity in MCF-7 cell line. (72h 
incubation) 
 
         Cytotoxicity evaluation7 indicates any of the changes on these two groups leads to significant 
potency loss (Figure 2.4). The cytotoxicity data further confirmed the irreplaceable role of 
cinnamate and tiglate, and also suggested the optimal combination for ipomoeassin F to perform 
its biological activity to be the aromatic α,β-unsaturated ester at C-4-Glcp and an aliphatic α,β-
unsaturated ester at C-3-Glcp. 
2.1.4. Structure-activity information from hydrophilic moieties modification  
         Ipomoeassin F is an amphiphilic glycoconjugate with only two hydrophilic hydroxyl groups 
at 3-OH-Fucp and 2-OH-Glcp. To better understand the function of the two groups in the molecular, 
we designed analogue 2.11 and 2.12 by introducing acetylation to the corresponding site and then 
evaluate the cytotoxicity on breast cell lines (Figure 2.5).   
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Figure 2. 5. Structures of ipomoeassin F analogues 2.11-2.12. 
 
         The cytotoxicity data indicates that amphiphilic character is a one of the important factors 
that retain the molecular biologic activity (Table 2.4). The two hydrophilic sites may serve as an 
exit tunnel to the aqueous environment and maintain the conformational stability. With a 
hydrophilic hydroxyl group left at 2-OH-Glcp, analogue 2.11 still exhibit strong potency even its 
potency decreases compared with ipomoeassin F. But analogue 2.12 on the other hand, totally lost 
its biological activity, which may be caused by poor aqueous solubility due to lack of hydrophilic 
group.   




MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.11 16.5 216 24.0  
2.12 >10,000 >10,000 NDb  
a The data were obtained from at least two independent experiments with the same condition, 
and the standard errors are within 20%; b ND = not determined. 
2.1.5. Structure-activity information from aglycone modification  
2.1.5.1. Impact of stereogenic center C-11 on ipomoeassin F bioactivity.   
         Within aglycone of ipomoeassin F, there is a unique stereogenic center at C-11 position. We 
hypothesized the exclusive structure may have a close relationship with molecular cytotoxicity, 
2.11 2.12 
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switching C-11S of ipomoeassin F into C-11R could inevitably impair its biological activity. To 
verify the hypothesis, we synthesized epimer analogue 2.13 and test its cytotoxicity against breast 
cancer cell lines (Figure 2.6).  
 
                          Figure 2. 6. Structures of ipomoeassin F and its C-11R epimer 2.13. 
         As expected, the cytotoxicity result perfectly supported the hypothesis.8 Cytotoxicity of 
constructed C-11R epimer leads to a 38-fold potency loss in MDA-MB-231 cytotoxicity assay 
compared with C-11S configuration of ipomoeassin F, giving the conclusion that C-11S is a 
favorable configuration for the impressive cytotoxicity.  




MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.13 240.2 830.7 159.2  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%. 
2.1.5.2. Impact of open-chain aglycone on ipomoeassin F bioactivity.   
         Other than chiral center, cyclic structure framework is another key character of ipomoeassin 
F. In literature, people believe cyclic structure framework is critical in retaining macrocycle 
biological activities.9-10 In order to clarify whether this hypothesis is applicable to the macrocyclic 
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skeleton of ipomoeassin F, we designed an open-chain analogue 2.14 and its terminal reduced 
analogue 2.15 to expel the disturbance introduced by terminal double bond (Figure 2.7).  
 
Figure 2. 7. Structures of ipomoeassin F analogues 2.14 and 2.15. 
         However, the cytotoxicity result doesn’t quite follow the hypothesis. Open chain analogue 
2.14 retained good potency even though experience some limited cytotoxicity loss (Table 2.6). 
While reducing the double bond, the analogue 2.15 recovered the cytotoxicity obviously, leaving 
the impression that integrity of macrocyclic structure is not the key requirement for maintaining 
high biological activity in ipomoeassin F. 




MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.14 59.1 124 151  
2.15 18.8 78.2 11.8  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%. 
         Cytotoxicity data conveyed another interesting piece of information that interruption of the 
ring structure of ipomoeassin F evidently improve its selectivity. Before opening the cyclic 
structure, the selectivity index (IC50 values in MCF-10A / IC50 in MDA-MB-231) is 0.84. But 
when the ring structure is opened, this index increases dramatically to 2.55. However, as double 
2.14 2.15 
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bond in open chain reduced, the index drops back to 0.63. The variation of selectivity index 
suggests double bond in open chain terminal increase the selectivity of this macrocyclic glycoside, 
providing valuable information for future anti-cancer drug development.    
2.1.5.3. Impact of cyclic structure size on ipomoeassin F bioactivity.   
         Although the cytotoxicity data of open chain analogues is not aligned with literature, the 
import role of cyclic structure in ipmoeassin F biological activity is not ignorable. Even so, the 
influence of cyclic structure size to ipomoeassin F potency is not fully understood. So, we try to 
change the ring size by adding (2.16) or chopping (2.17) one or two members to the skeleton and 
explore the impact on its cytotoxicity. 
 
Figure 2. 8. Structures of ipomoeassin F and its analogues 2.16 and 2.17. 
         Since cyclic structure is one of the exclusive characters, the modification on the size lead to 
evident cytotoxicity difference (Table 2.7). Interestingly, as aglycon ring size becomes larger, 
molecular potency increases 4-fold. On the other hand, decreasing the ring size gives rise to even 
10-fold potency loss. A possible explanation for the bioactivity change is that as the size of aglycon 
increase, the molecular becomes easier to be incarcerated after binding to the target protein 
functional pocket, facilitating compound-target protein interaction. The result not only firmly 
supports the critical role of cyclic structure framework in maintaining biological activities, but also 
26 
provides solid evidence for the conclusion that overall lipophilicity is vital to maintain potency of 
ipomoeassin F. 




MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.16 1.3 9.1 0.6  
2.17 67.8 291.6 98.6  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%. 
2.1.6. Structure-activity information from fucose modification  
         D-Glcp and D-Fucp connecting with functional groups constitute the core structure of 
ipomoeassin F. According to the structure-activity relationship discussed above, certain 
modifications around D-Fucp didn’t significantly diminish the molecular cytotoxicity. To further 
explore the biological contribution of D-Fucp, we plan to truncate the whole fucose and design 
monosaccharide analogues 2.18 and 2.19 (Figure 2.9).   
 
Figure 2. 9. Structures of ipomoeassin F analogues 2.18 and 2.19. 
         The biological activity of analogues was evaluated against two breast cancer cell lines MDA-
MB-231 and MCF-7.11 Compared with ipmoeassin F, the two monosaccharides almost lost any 
inhibition of cell proliferation (Figure 2.10). Without doubt, D-Fucp is indispensable in the 
2.18 2.19 
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bioactivities of impomoeassin F. Accompanied with the information that modification of 
peripheral groups could cause very limited potency loss, it is not hard to come to the conclusion 
that the existence of D-Fucp provides stability to maintain the appropriate confirmation of 
ipomoeassin F structure, so it can work properly with the target protein.            
A.                                                              B. 
     
Figure 2. 10. Viability curves of ipomoeassin F and analogues 2.18 and 2.19 in breast cancer cell 
lines: (A) Cytotoxicity in MDA-MB-231 cell line; (B) Cytotoxicity in MCF-7 cell line. (72h 
incubation) 
2.1.7. Summary of structure-activity relationship study  
         In conclusion, by deliberate design, synthesis and cytotoxicity screening, we built up a 
systematic analogue library of ipomoeassin F. With the help of complicated structure modification 
vs cytotoxicity variation, the importance of each moiety was illuminated. The influence 
significance of different groups can be summarized at the rank of D-
Fucp >cinnamate >tiglate >alkene in cinnamate > alkene in tiglate > acetate > 3-OH-Fucp >cyclic 
skeleton ≈ ketone (Figure 2.11).  
         As an amphiphilic glycoconjugate, both hydrophobic groups and hydrophilic groups are 
indispensable for ipomoeassin F to perform its cytotoxicity. Hydrophilic groups, work as a vessel, 
help the overall molecule stay soluble in an aqueous environment so that it could be transported 
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into the cell. Hydrophobic groups, work as anchors and functionality portions, facilitate 
ipomoeassin F anchoring inside hydrophobic binding pocket and interact with target protein in the 
hydrophobic environment. Therefore, increasing hydrophobicity appropriately would favor its 
interaction with target protein. However, introduction of hydrophobicity by blocking hydrophilic 
moieties will inevitably damage the potency due to the significant aqueous solubility loss.   
 
Figure2. 11. Cytotoxicity loss by pharmacophore editing. 
 
         All characteristic structures work together to maintain the distinguish potency of 
ipomoeassin F. Chiral center C-11R keeps ipomoeassin F function at an optimal configuration; 
ring structure aglycon helps the molecular stay firmly inside binding pocket facilitating further 
interaction with protein domains. Opening the cyclic structure retains cytotoxicity probably by 
limited conformational disturbance, and the modification evidently uncovered selectivity increase, 
providing a new approach for clinical drug development. The dramatical cytotoxicity disturbance 
along with modification of two α,β-unsaturated esters cinnamate and tiglate suggests that they may 
play important role in interacting with the target protein by covalent binding or strong non-valent 
interaction, directing a promising way for further MOA study and target protein identification.  
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2.2.  Probe Design and Selection  
         Chemical probe is a series of modified molecular maintain original drug structural and bio-
active similarity but has certain key chemical and structural differences.12 The introduced key 
functional groups are essential to illustrate the unknown compound-cell/bio-molecular interaction 
and support unbiased interpretation of biological experiments. Developing appropriate chemical 
probe tool kit more than once has been documented to be beneficial towards action mode 
exploration and drug development.   
         Scientists at Pfizer Inc recently published the four pillars philosophy (Figure 2.12) in 
directing successful drug development program by retrospective analyzing 44 drug programs and 
2 clinical trials.13 Pillar 1 involves the efficacy exposure of probes at the expected site of action. 
The first pillar confirms cellular permeability of the probes by evaluating the pharmacologically 
relevant concentrations at the target site, therefore rule out the possibility that the response is due 
to unspecific binding. The pillar 2 proves target engagement and is the most challenging validation. 
But appropriate strategy approach such as activity-based proteomics profiling, fluorophore 
introduction would facilitate target identification and validation.  Pillar 3 and pillar 4 further 
confirm the pharmacokinetic and pharmacodynamic properties of a drug to be developed and 
phenotype disturbance after probe application. Probes with poor access to the site of action would 
lead to the lack of pharmacological (pillar 3) or phenotypic (pillar 4) response, resulting in false 
negative result. According to their analysis, failed projects often are not able to fulfill some or all 
the four pillars.  
         With the employment of cytotoxicity screening, the different moiety properties of 
ipomoeassin F is well established. According to information collected from SAR study, most vital 
factors for maintaining ipomoeassin F cytotoxicity are position of cinnamate and tiglate, existence 
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of the two α,β-unsaturated double bond, existence of aromatic ring structure in cinnamate and the 
complete D-Fucp structure.  In order to avoid disturbing molecular potency at minimum extent, 
we design our probe by introducing functional groups at para position of the aromatic ring structure 
to push introduced moieties away from core structure as far as possible.   
 
 
Figure 2. 12. The four pillars of cell-based target validation using chemical probes.13 
2.2.1. Probes for stepwise target protein identification  
         Active-based protein profiling (ABPP) is a typical approach to identify target protein. Probes 
for ABPP typically consist of an active site, a linker and a traceable tag. These three constituents 
greatly facilitate the target identification efficacy, however, too many structures in the probe on 
the other hand causes steric hinderance between probe and the target protein, influencing the 
chance of successfully binding to expected targeting site.  
         To overcome this disadvantage, stepwise click chemistry is employed for target identification. 
In our project, we designed probe 2.20 by introducing alkyne into para position of benzene ring. 
According to our SAR study, α,β-unsaturated double bond is one of the most critical structure that 
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help maintain molecular cytotoxicity. As a result, a new analogue 2.21 with all double bonds 
reduced would be expected to be inactive, so that it can be used as an ideal negative control.  
         As expected, slight modifications on aromatic ring did not disturb the biological activity 
too much (Figure 2.13B), indicating the change have little impact on MOA of ipomoeassin F. 
A.  
 
B.                                                                    
 
 
Figure 2. 13. Structure and cytotoxicity of ipomoeassin F analogues 2.20 and 2.21. (A) Structure 
of 2.20 and 2.21. (B). Viability curve of 2.20, 2.21 and ipomoeassin F in MDA-MB-231 and MCF-
7 (72h incubation).   
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It is a high probability that 2.20 could bind the same target, hence introduction of traceable tags 
like fluorophore or biotin by click chemistry reaction following 2.20 specifically binding the 
target protein may provide great chance to capture and trace the target protein (Figure 2.14). 
Being an inactive analogue, 2.21 is a perfect corresponding side by side negative control of any 





Figure 2. 14. Diagram of stepwise target protein identification. (A) Target protein labelling; (B) 
Introduction of traceable moieties for protein isolation and identification.   
2.2.2. Probes for ABPP by fluorophore reporter  
         Fluorophore is commonly used strategies for tracking biological action mode not only in 
subcellular level but also in molecular level studies due to its high sensitivity. To make good use 
of the great advantage, we designed fluorescent probes 2.22 - 2.28 (Figure 2.15).    
= 
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Figure 2. 15. Structure of ipomoeassin F analogues 2.22-2.28. 
 
         Based on cytotoxicity screening in breast cancer line MDA-MB-231 and MCF-7, analogue 
2.22, 2.23, 2.26, 2.27 were expelled due to significant potency loss (Table 2.8). Both coumarin-
coupled probe 2.24 and NBD-coupled probe 2.28 retained substantial cytotoxicity with 2.28 being 
even more potent than ipomoeassin F. Unfortunately, 2.28 underwent photobleaching very easily 







presumably due to an internal photo-induced electron transfer effect combined with its shorter 
excitation maximum (365 nm). Fluorescent signal from probe 2.25 was strong and stable in 
different situation, and therefore was selected for further cell imagine studies.     




MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.22 5,500.3 5,825.1 NDb  
2.23 8,547.6 10,565 ND  
2.24 8.9 172.2 11.3  
2.25 253.4 172.2 133.8  
2.26 7,225.5 >25,000 ND  
2.27 1,270.6 >25,000 ND  
2.28 2.8  21.1  2.0  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%; b ND = not determined. 
2.2.3. Probes for ABPP by affinity tag reporter 
         Biotin affinity pull down experiment is a widely used approach for target protein purification 
and identification. The strategy is based on strong non-covalent binding between biotin and 
streptavidin, specifically reserving target protein that forms complex with biotin containing probes. 
Since high specificity is a great advantage of biotin affinity target protein identification, we 
designed probes 2.29 - 2.33 (Figure 2.16). 2.29 is expected to be an active probe with short linker, 
its reduced form 2.30 is expected to be corresponding negative control.   
         Accordingly, probe 2.31 and probe 2.33 are designed to be active probes with long linkers. 
In order to better exclude noise signal from non-specific binding protein, we introduced a 
photocleavage moiety into the linker.  Probe 2.32, a reduced form of 2.33, was designed to be the 
corresponding negative control.  
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Figure2. 16. Structures of ipomoeassin F analogues 2.29 - 2.33. 
 
         As expected, active analogues 2.29, 2.31 and 2.33 keep the cytotoxicity loss within 5-fold 
(Table 2.9). Among these potential applicable probes, 2.31 almost withholds disturbance of 
structure modification, suggesting the high probability that it shares identical target protein as 
ipomoeassin F. Probes 2.30 and 2.32 were proved to be perfect negative controls that have no 
biological activity against test cells.  
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MDA-MB-231 MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
2.29 29.5  187.4  21.7  
2.30 >25,000 >25,000 NDb  
2.31 7.0  19.8  5.1  
2.32 >25,000 25,000 ND  
2.33 24.1 225.3 21.9  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%; b ND = not determined. 
2.2.4. Summary of Probes design and selection.  
         Active based protein profiling (ABPP) is a widely accepted as an efficiency strategy for 
target protein identification. According to our systematic SAR study of ipomoeassin F, we 
designed and tested probe 2.20 and its corresponding negative control 2.21 for stepwise ABPP. 
We designed a couple of fluorescent probes and picked up 2.25 for future study because of its 
acceptable potency, strong fluorescent intensity and fluorophore stability. We also designed biotin 
probes and verified their applicability from their cytotoxicity. 2.29 and 2.30 are selected to be short 
linker pairs for affinity purification; 2.31 is selected to be an ideal candidate for MOA study; 2.32 
and 2.33 are selected to be long linker pairs for affinity purification.   
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CHAPTER 3. IPMOEASSIN F TARGET PROTEIN IDENTIFICATION AND 
VALIDATION  
3.1. Abstract  
         Ipomoeassin F is a potent natural cytotoxin that inhibits growth of many tumor cell lines with 
single-digit nanomolar potency by an undefined mechanism. However, its biological and 
pharmacological properties have remained largely unexplored. Building upon our earlier 
achievements in total synthesis and medicinal chemistry, we used chemical proteomics to identify 
Sec61α (protein transport protein Sec61 subunit alpha isoform 1), the pore-forming subunit of the 
Sec61 protein translocon, as a direct binding partner of ipomoeassin F in living cells. The 
interaction is specific and strong enough to survive lysis conditions, enabling ipomoeassin F to 
pull down Sec61α from live cells, yet it is also reversible as judged by fluorescent streptavidin 
staining and reverse competition. Sec61α provides the central subunit of the ER protein 
translocation complex, and the binding of ipomoeassin F results in cell proliferation inhibition. 
Therefore, ipomoeassin F represents the first plant-derived, carbohydrate-based member of a novel 
structural class that offers new opportunities to explore Sec61α function and to further explore its 
potential as a therapeutic target for drug discovery.   
3.2.  Introduction 
         Historically, natural products have significantly contributed to the development of drugs for 
human disorders,1 most notably as anticancer chemotherapeutics.2 Structurally and functionally 
unique natural products also provide a spectrum of valuable chemical tools for examining 
biological systems in translational biomedical research.3,4 To continue our battle against various 
unsolved problems of human health, including those arising from drug resistance, it is crucial to 
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systematically investigate underexplored areas of existing chemical space such as those offered by 
bioactive natural products with unique structures and/or mechanisms.5 
         Resin glycosides, also called glycoresins, are a large collection of amphiphilic glycolipids 
isolated from the morning glory family of plants,6 and these compounds are considered active 
ingredients of many morning glory-based traditional medicines that are used worldwide. Resin 
glycosides consist of a differently-acylated oligosaccharide glycosylated with a mono- or 
dihydroxy C14 or C16 fatty acid, with more than 300 family members discovered to date. Through 
an ester bond, the fatty acid chain is usually folded back to form a macrolactone ring of various 
sizes spanning one or more carbohydrate units. Because of their unique macrocyclic architecture 
with embedded carbohydrates, and their broad spectrum of biological activities exhibited in 
phenotypic screens, resin glycosides have attracted considerable attention from the synthetic 
chemistry community, but not much beyond.7-9 
         In 2005, a new family of glycoresins, ipomoeassins A–E, was isolated from the leaves of 
Ipomoea squamosa found in the Suriname rainforest and shown to inhibit the proliferation of 
A2780 human ovarian cancer cells.10 Among these compounds, ipomoeassin D (Figure 1) 
displayed the greatest potency with an IC50 value of 35 nM. Two years later, a new member of the 
family, ipomoeassin F (Figure 1), was isolated and showed a cytotoxicity comparable to 
ipomoeassin D.11 Because of their promising antiproliferative activity and unique molecular 
skeleton with carbohydrates being part of the macrocycle, these newly discovered natural 
glycoconjugates quickly inspired synthetic chemists, including ourselves, to tackle their total 
syntheses.12-16 Subsequently, ipomoeassin F was confirmed to be the most cytotoxic resin 
glycoside discovered to date with single-digit nanomolar IC50 values against several cancer-
derived cell lines.13 Intriguingly, ipomoeassins A and F (see Figure 1) have distinct cytotoxicity 
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profiles, as revealed in the NCI 60-cell lines screen, suggesting that the ipomoeassins may possess 
an unusual mode of action.16,17 On this basis, ipomoeassin F is a very promising candidate for 
molecular probe and chemotherapeutic development; however, the absence of knowledge about 
the cellular targets of ipomoeassin F has significantly impeded such efforts. To overcome this 
challenge, after improving our understanding of the structure–activity relationship (SAR) of 
ipomoeassin F through medicinal chemistry studies,18-20 we employed a chemical proteomics 
approach to identify its binding partner(s) in human cells. Here we describe the evolution of our 
chemoproteomic studies that enabled the discovery of Sec61α (protein transport protein Sec61 
subunitalpha isoform 1) as a primary molecular target of ipomoeassin F, and our subsequent 
mechanistic investigations which validate this component as a key target. We define the inhibitory 
effects of ipomoeassin F on Sec61-mediated bioactivity within endoplasmic reticulum (ER), 
corroborating our contemporaneous observations of the potent inhibition of cellular secretion by 
ipomoeassin F. 
 
Figure 3. 1. Structures of ipomoeassins A, D, and F. 
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3.3. Results and Discussion  
3.3.1. Proteomics Evaluations of Chemical Probes derived from Ipomoeassin F.  
   Michael acceptor systems are present in many electrophilic natural products, allowing the 
formation of covalent adducts with bio-macromolecules, which are often responsible for their 
biological activities.21 Because of significant activity loss (up to 160-fold) after reducing one of 
the two double bonds in the α,β-unsaturated esters to a single bond,22 we hypothesized that the 
cinnamate and/or the tiglate (Figure 3.1) may enable irreversible binding between ipomoeassin F 
and its biological target(s). Therefore, we initially designed and synthesized a potential activity-
based probe23-25 3.1 (Figure 3.2) by introducing a small propargyloxy group to the para position of 
the benzene ring. 
 
Figure 3. 2. Structure of ipomoeassin F analogues 3.1-3.3. 
 
   With probe 3.1 in hand, we conducted activity-based protein profiling experiments for target 
identification both in the soluble fraction of cell lysates made from MDA-MB-231 breast cancer 
cells and live MDA-MB-231 cells. Unfortunately, after in situ click chemistry with a fluorescent 
rhodamine azide 26, we detected no differences in labeled proteins between negative control (lane 
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1), probe 3.1 (lane 2), and probe 3.1 plus ipomoeassin F (competition; lane 3) (Figure S2A), while 
an unrelated probe used as a positive control for pulldown gave clear signals (Figure S2A, lanes 4 
and 5). We considered two possible explanations for this negative result: firstly, ipomoeassin F is 
not a covalent protein modifier; secondly, target proteins of ipomoeassin F are in low abundance. 
Due to the dramatic loss in activity with alkene-reduced compounds,22 we favored the second 
possibility. 
Table 3. 1. Cytotoxicity (IC50, nM) of Ipomoeassin F and Its Probes 3.1-3.7a 
 
 
MDA-MB-231b MCF7 MCF-10A  
Ipomoeassin F 6.3 36.4 5.3  
3.1 6.3 22.2 9.6  
3.2 29.5 187.4 21.7  
3.3 7.0 19.8 5.1  
3.4 24.1 225.3 21.9  
3.5 > 25,000 > 25,000 NDc  
3.6 > 25,000 > 25,000 ND  
3.7 253.4 172.2 133.8  
a The data were obtained from at least two independent experiments, and the standard errors 
are within 20%; b See Figure S1 for IC50 curves; 
cND = not determined. 
   With probe 3.1 in hand, we conducted activity-based protein profiling experiments for target 
identification both in the soluble fraction of cell lysates made from MDA-MB-231 breast cancer 
cells and live MDA-MB-231 cells. Unfortunately, after in situ click chemistry with a fluorescent 
rhodamine azide 26, we detected no differences in labeled proteins between negative control (lane 
1), probe 3.1 (lane 2), and probe 3.1 plus ipomoeassin F (competition; lane 3) (Figure S2A), while 
an unrelated probe used as a positive control for pulldown gave clear signals (Figure S2A, lanes 4 
and 5). We considered two possible explanations for this negative result: firstly, ipomoeassin F is 
not a covalent protein modifier; secondly, target proteins of ipomoeassin F are in low abundance. 
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Due to the dramatic loss in activity with alkene-reduced compounds,22 we favored the second 
possibility. 
   In order to enrich for relatively low abundance cellular proteins, we next synthesized a biotin-
labeled analogue 3.2 of ipomoeassin F by reacting the alkyne probe 3.1 with biotin azide 27 under 
chemo-selective copper-catalyzed alkyne-azide coupling (CuAAC) conditions.28 The synthesis 
was successful in producing biotin probe 3.2 that remained cytotoxic (Table 3.1), showing only 
~5-fold decrease. After incubating 3.2 with either detergent solubilized cell lysate or intact cells, 
we ued streptavidin beads to recover the biotin probe 3.2-bound proteins followed by 
electrophoresis and silver staining of the captured material. However, no proteins were selectively 
enriched by probe 3.2 (Figures S3A and S3C, lanes 1 to 3), nor was any enrichment apparent when 
these samples were probed using a fluorophore-labeled streptavidin (Figure S3B, lanes 1 to 3). 
   We hypothesized that if the target protein(s) of ipomoeassin F is of relatively low abundance, 
then endogenously biotinylated proteins could outcompete, and thereby mask, any positive signal. 
To minimize interference from endogenously biotinylated proteins, we synthesized a new biotin 
probe 3.3 (Figure 3.2) containing a photo-cleavable nitrobenzene moiety29 by coupling the alkyne 
analogue 3.1 with the biotin azide fragment containing an o-nitrobenzyl photolabile linker, the 
latter synthesized by modifying previously reported procedures26-28 . Notably, the capacity of 3.3 
to inhibit cancer cell proliferation was close to that of parental ipomoeassin F (Table 3.1), despite 
the large size of the appendage at the para-position of the cinnamate benzene ring. We then used 
probe 3.3 to label target proteins in live MDA-MB-231 cells, performed a streptavidin pulldown 
on the resulting cell lysate and selectively released bound proteins by UV photocleavage. When 
the resulting products were analyzed by SDS-PAGE, probe 3.3 strongly enriched a ~40 kDa 
protein and, to a lesser extent, a second protein of ~100 kDa (Figure 3.2A, lane 2, red arrows), 
45 
both of which were absent from the negative control (Figure 3.3A, lane 1). In support of their bona 
fide interaction with 3.3, these two proteins were lost when a 100-fold excess of unmodified 
ipomoeassin F was included during the incubation (Figure 3.3A, lane 3). Because no proteins were 
selectively recovered with probe 3.3 when it was incubated with detergent-solubilized (1% NP40 
and 0.25% sodium deoxycholate) extracts of MDA-MB-231 cells (Figure S3C, lanes 1, 4 and 5), 
we believe that the interaction between ipomoeassin F and its target protein(s) may require a 
particular subcellular environment that is detergent sensitive. 
 
Figure 3. 3. Affinity pulldown using probe 3.3 with (A) or without (B) photo cleavage. Red 
arrows indicate positive results; (C) Target validation by western blot with a Sec61α antibody. 
Ipom-F, ipomoeassin F; AP, affinity pulldown. 
 
   We next investigated whether photocleavage is essential for the selective recovery of the two 
putative target protein bands using probe 3.3. Strikingly, the ~40 kDa protein was also recovered 
without photocleavage. It was substantially enriched by 3.3 when total streptavidin-bound products 
were analyzed, and was lost in the presence of excess ipomoeassin F (Figure 3.3B, lanes 1–3). In 
contrast, an enrichment of the ~100 kDa component under these conditions was not apparent 










         
Figure 3. 4. Structure and cytotoxicity of ipomoeassin F analogues 3.4-3.5. (A) Structure of 
probe 3.4 and 3.5; (B) Viability curve of 3.3, 3.4, 3.5 and ipomoeassin F in MDA-MB-231 and 
MCF-7 (72h incubation). 
 
   To further investigate the factors that facilitate ~40 kDa protein recovery, we designed biotin 
probe 3.4 (Figure 3.4) which contains -N- rather than -O- in the linker compared with probe 3.3 
and its reduced analogue 3.5 (Figure 3.4) as reference compound. While substituting -N- with -O- 
in the linker triggers limited cytotoxicity disturbance, further reduction of the two α,β-unsaturated 
double bonds leads to significant loss of the biological activity (Figure 3.4B). Then we performed 
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biotin affinity pull down parallel with different probes and analyzed collected sample with SDS-
PAGE gel. Probe 3.4 (Figure 3.5, lane 4) specifically enriched ~40 kDa protein the same amount 
of probe 3.3 (Figure 3.5, lane 2), inactive probe 3.5 (Figure 3.5, lane 3) exhibit no specific 
enrichment as reference group.  
 
Figure 3. 5. Affinity pulldown using probe 3.3, 3.4 and 3.5. Cells are treated with 20nM 1h 
accordingly in each group.  
 
   Since photocleavage and subtle linker change were not essential for probe 3.3 to selectively 
recover the 40 kDa protein, it is very likely that the increased linker length between the biotin 
moiety and the ipomoeassin F region, but not its capacity for selective cleavage, significantly 
improved the performance of probe 3.3 over probe 3.2. Another factor that plays critical role in 
selectively isolating the 40 kDa protein is the exitance of double bound in cinnamate and tiglate 
groups. The conclusion is supported by absence of the ~40 kDa protein recovery in 20nM 
incubation after reducing the two double bonds (Figure 3.5, lane 2 and 3), even with 500 nM of 
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3.5 affinity pull down (Figure S4B, lanes 1 and 4).  Our data also suggest that, once formed, the 
complex between probe 3.3 and the ~40 kDa protein is tight and can survive detergent mediated 
cell lysis. This is further supported by pulldown of the ~40 kDa target protein with low 
concentrations of probe 3.3 (10 nM) and ipomoeassin F (50 nM) (Figure S4A, lanes 1–3).  
   We next submitted both the ~40 kDa protein(s) (Figure 3.3B, lane 2) and the corresponding 
regions of the gel for the negative control (Figure 3.3B, lane 1) and the ipomoeassin F competition 
sample (Figure 3.3B, lane 3) for mass spectrometry analysis. When spectral counts were compared, 
Sec61α (protein transport protein Sec61 subunit alpha isoform 1) stood out as the only protein that 
was both substantially enriched in the pulldown with probe 3.3 and showed a corresponding 
reduction when excess ipomoeassin F was present (Table S1). The selective recovery of Sec61α 
by probe 3.3 was further confirmed by Western blotting (Figure 3C, cf. signals between input and 
AP). 
   To further support Sec61α as a target protein responsible for the biological activity of 
ipomoeassin F, we synthesized another reference compound 3.6 (Figure 3.6 and Table 3.1) by 
removing both double bonds in cinnamate and tiglate. Inactive analogue 3.6 was ineffective at 
competing with probe 3.3 binding, even when 3.6 was present in 50-fold excess (Figure S4B, cf. 
lanes 1 to 3). Taken together, these findings further support the specificity of Sec61α as a primary 
cellular target of ipomoeassin F. 
 
Figure 3. 6. Structures of ipomoeassins F analogues 3.1 and 3.6. 
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3.3.2. Cell Imaging Studies.  
         The Sec61 protein translocon plays an essential role in translocating newly synthesized 
membrane and secretory polypeptides into and across the membrane of the endoplasmic reticulum 
(ER).30,31 Sec61α forms the membrane conduit that nascent secretory polypeptides pass through. 
To examine the subcellular localization of ipomoeassin F, we performed live cell imaging studies 
using fluorescent analogue 3.7 (Figure 3.7) prepared from alkyne probe 3.1 using CuAAC. To 
overcome the low fluorescent signal caused by internal photo-induced electron transfer and 
photobleaching often encountered in fluorescent probe studies, rhodamine analogue 3.7 was 
synthesized from the rhodamine azide precursor. Although 3.7 is between 5- and 40-fold less 
potent than ipomoeassin F depending on the cell type analyzed, it retains substantial cytotoxicity 
when compared to inactive analogues 3.5 and 3.6 (see Table 3.1), and we therefore used it for our 
imaging studies.  
 
Figure 3. 7. Structures of fluorescent derivative 3.7 of ipomoeassin F. 
 
         Subsequently, we confirmed that 3.7 could penetrate the cell membrane in a concentration- 
and time dependent manner and gave a strong fluorescent signal. Hence, 3.7 stained cells within 
30 mins when present at 2 μM, but took >3 h to give clear images when used at 20 nM. When cells 
labelled with 3.7 were co-stained with markers for either the ER or the nucleus, it was apparent 
that 3.7 strongly labeled the ER (Figure 3.8), but not the nucleus (Figure S5A). To confirm the 
specificity of ER labelling by 3.7, competition experiments were performed using ipomoeassin F 
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or inactive compound 3.6. The fluorescence signal of 3.7 was almost completely abolished when 
the cells were preincubated for 30 minutes with a 100-fold excess of free ipomoeassin F (Figure 
S5B), yet preincubation with compound 3.6 had little effect (Figure S5C). The apparent ER 
localization of the cellular interacting partner(s) of ipomoeassin F strongly supports the notion that 
its target is Sec61α. 
 
Figure 3. 8. Cell imaging studies with fluorescent probe 3.7 in MDA-MB-231 cells. Rhodamine-
conjugated ipomoeassin F analogue 3.7 (0.2 μM) was added to cells and after 1 hours, cells were 
imaged to analyze localization of 3.7 relative to ER staining. 
3.3.3. Pulldown from ER Microsomes.  
         As evidenced by the negative results from our pulldown experiments using cell lysates 
prepared with detergent, we propose that the membrane environment of the ER may be required 
to maintain Sec61α in a conformation that can bind to ipomoeassin F effectively. In this regard, 
it would be unlikely that purified Sec61α alone could recapitulate a direct interaction with the 
natural product. However, since the biological function of Sec61α is maintained in isolated ER 
microsomes (provide by cooperation lab),32 and once pre-bound to probe 3.3 in intact cells the 
resulting complex appears stable to detergent treatment (Figures 3.2A and 3.2B), we attempted to 
pulldown Sec61α from purified ER-derived microsomes. After incubation with probe 3.3 and 
detergent solubilization (10% n-dodecyl-ß-D-maltoside) to release biotin-bound proteins from the 
3.7 
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phospholipid bilayer, only a single protein was visible after pulldown (Figure S6A). The identity 
of this product was confirmed as Sec61α by western blotting (Figure S6B). This finding strongly 
supports our previous conclusion made with live cells, namely that Sec61α directly interacts with 
ipomoeassin F. 
3.3.4. Pulldown from ER Microsomes.  
         As evidenced by the negative results from our pulldown experiments using cell lysates 
prepared with detergent, we propose that the membrane environment of the ER may be required 
to maintain Sec61α in a conformation that can bind to ipomoeassin F effectively. In this regard, 
it would be unlikely that purified Sec61α alone could recapitulate a direct interaction with the 
natural product. However, since the biological function of Sec61α is maintained in isolated ER 
microsomes,32 and once pre-bound to probe 3.3 in intact cells the resulting complex appears stable 
to detergent treatment (Figures 3A and 3B), we attempted to pulldown Sec61α from purified ER-
derived microsomes. After incubation with probe 3.3 and detergent solubilization (10% n-dodecyl-
ß-D-maltoside) to release biotin-bound proteins from the phospholipid bilayer, only a single 
protein was visible after pulldown (Figure S6A). The identity of this product was confirmed as 
Sec61α by western blotting (Figure S6B). This finding strongly supports our previous conclusion 
made with live cells, namely that Sec61α directly interacts with ipomoeassin F. 
3.3.5. ipomoeassin F and Sec61α interaction mode exploration.  
         According to the information we got from biotin affinity pull down experiment, Sec61α can 
form tight complex with probe 3.3 by direct interaction even at the concentration of 10nM in 
membrane complete environment. The question that whether this complex sustained by a covalent 
binding or strong non-covalent intermolecular interaction attracted our attention.  
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         Since IC50 of probe 3.3 against MDA-MB-231 is 7.0nM, we further narrowed down its work 
concentration down to 5nM and found ~40 kDa protein enrichment still could be detectable (Figure 
S4C, lane 1), suggesting the binding between probe 3.3 and Sec61α is very sensitive and strong.  
Considering 5-fold of ipomoeassin F can easily keep the probe 3.3 out of binding site (Figure S4A) 
and the single digital nanomolar cytotoxicity IC50 value against multiple cell lines, the connection 
between ipomoeassin F and Sec61α seems to be a covalent binding.  
         Nevertheless, fluorescent streptavidin staining indicates that a stable covalent adduct 
between the ~40 kDa protein and probe 3.3 was not formed under SDS-PAGE electrophoresis 
(Figure S3B, lanes 4 and 5). The contradictory guided us to have a second thought on the 
understanding about the binding mode between ipomoeassin F and target protein Sec61α.  
         Traditional competition is performed by the order of treating cells with probes (analogue 3.3) 
followed by half an hour original compound (ipomoeassin F) management. The result from the 
procedure would provide solid evidence that probe 3.3 and ipomoeassin F share the identical target, 
however the result could not provide evidence to convince people about the binding mode. To 
overcome this disadvantage, we switch the order of cell management. If the ipomoeassin F-protein 
complex binding is covalent, ipomoeassin F would have little chance to squeeze the probe 3.3 out 
binding pocket when treating cell after probe 3.3 management. Vice versa, If the secondary 
treatment of ipomoeassin F can peel its probe 3.3 off after the probe-protein complex fully 
generated, it is more likely that binding is non-covalent.  
         We gradually increase the reverse 100-fold competition intensity in the order of: ipomoeassin 
F 0.5h treatment followed by 1h probe 3.3 management (Figure 3.9A, lane 4), ipomoeassin F 1h 
treatment followed by 1h probe 3.3 management (Figure 3.9B, lane 4). Short time reverse 
competition competes away very limited protein binding compared with traditional pulldown 
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experiment (Figure 3.9A, lane 2). But with the elongation of competition time, more and more 
probe-protein complex become dissociated (Figure 3.9B, lane 4). The increase of competition 
effectiveness in the reverse treatment supports the idea that ipomoeassin F targets Sec61α most 





Figure 3. 9. traditional completion and reverse competition between ipomoeassin F and analogue 
3.3: (A) ipomoeassin F 0.5h competition after 1h 3.3 incubation; (B) ipomoeassin F 1h competition 
after 1h 3.3 incubation.  
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3.4.Conclusions  
         Here, we report comprehensive chemical biology studies of ipomoeassin F to understand the 
molecular basis for its potent cytotoxicity. By designing and evolving our chemical probes on an 
empirical basis, Sec61α was ultimately identified and validated as a direct and physiologically 
relevant target of ipomoeassin F. The absence of fluorescent streptavidin staining we observed 
indicates ipomoeassin F is unlikely to form a stable covalent complex with Sec61α, despite the 
presence of two Michael acceptor systems in its structure (cinnamate and tiglate, Figure 3.1). 
Moreover, reverse competition supports the non-covalent binding between ipomoeassin F and 
Sec61α. We therefore conclude that the pulldown of Sec61α with probe 3.3 represents a successful 
biotin affinity enrichment of a non-covalent ligand-membrane protein complex formed in live cells, 
most likely reflecting a slow disassociation rate of ipomoeassin F from Sec61α. The binding of 
ipomoeassin F to cellular Sec61α is supported by the ER staining seen with a fluorescent version 
of the compound, the highly selective pulldown of Sec61α from ER-derived microsomes and the 
ability of ipomoeassin F to compete with cotransin for Sec61α binding.  
         In short, we provide compelling evidence that the core α subunit of the Sec61 translocation 
complex is the major target for ipomoeassin F in a cellular context, thereby opening the way for 
the exploitation of ipomoeassin F for target-based drug discovery. More broadly, given its 
comparatively advantageous synthesis, we anticipate that ipomoeassin F and its analogues/probes 
will provide accessible new molecular tools that will help our efforts to fully define the molecular 
basis for Sec61-mediated protein translocation at the ER membrane. 
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3.5.Supporting Information  
3.5.1. Cytotoxicity Assay 
3.5.1.1. Cell Culture  
         Two human breast cancer cell lines (MDA-MB-231 and MCF7) and one human breast 
nontumorigenic epithelial cell line (MCF-10A) were maintained in a DMEM high glucose culture 
medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. The cells were 
grown in a humidified atmosphere of 5% CO2 and 95% air at 37 ºC. The culture medium was 
changed every 2–4 days depending on cell density. Cell cultures were passaged once a week using 
0.125% trypsin-EDTA to detach the cells from culture flasks/dishes.  
3.5.1.2. MTT Cytotoxicity Assay 
         Viable cells were counted with a hemocytometer immediately before each experiment. 
Experiments were done in triplicate. First, 100 μL of MCF7 cells at the density of 50,000 cells/mL 
were seeded in a 96-well plate (5,000 cells/well), which was incubated at 37 ºC and 5% CO2 
atmosphere for 24 h. The compounds were dissolved in DMSO (dimethyl sulfoxide) to make drug 
stocks (10 mM). The stock solutions were diluted with the complete DMEM high glucose culture 
medium to make a series of gradient fresh working solutions right before each test. Subsequently, 
the cells were treated with 100 μL of the freshly made gradient working solution in the total volume 
of 200 μL/well for 72 h. After that, the media were discarded and 200 μL of the fresh complete 
medium containing 10% of MTT stock solution (5 mg/mL) was added to each well. The plate was 
then incubated at 37 ºC and 5% CO2 for 3 h. Next, 180 μL of the medium was discarded from each 
well, and 180 μL of DMSO was added to each well to dissolve formazan crystals. Absorbance of 
formazan was detected by a microplate reader (BioTek Synergy H1) at 570 nm with 650 nm as the 
reference wavelength. The percentage of viability compared to the negative control (DMSO-
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treated cells) was determined. GraphPad Prism 6 software was used to make a plot of % 
viability versus sample concentration and to calculate the concentration at which a compound 
exhibited 50% cytotoxicity (IC50).  
3.5.1.3. AlamarBlue Cytotoxicity Assay  
         MDA-MB-231 and MCF-10A Viable cells were counted with a hemocytometer 
immediately before each experiment. Experiments were done in triplicate. First, 100 μL of MDA-
MB-231 cells or MCF10A cells at the density of 50,000 cells/mL was seeded in a 96-well plate 
(5,000 cells/well) and then incubated at 37 ºC and 5% CO2 for 24 h. The compounds were dissolved 
in DMSO (dimethyl sulfoxide) to make drug stocks (10 mM). The stock solutions were diluted 
with the complete DMEM high glucose culture medium to make a series of gradient fresh working 
solutions right before each test. Subsequently, the cells were treated with 100 μL of the freshly 
made gradient working solution in the total volume of 200 μL/well for 72 h. After that, the media 
were discarded and 200 μL of the fresh complete medium containing 10% of AlamarBlue 
(resazurin) stock solution (3 mg/27.15mL) (5 mg/mL) was added to each well. The plate was then 
incubated at 37 ºC and 5% CO2 for another 3 h. Emission of each well at 620 nm was detected by 
a microplate reader (BioTek Synergy H1) at excitation 580 nm. The percentage of viability 
compared to the negative control (DMSO-treated cells) was determined. GraphPad Prism 6 
software was used to make a plot of % viability versus sample concentration and to calculate the 
concentration at which a compound exhibited 50% cytotoxicity (IC50).  
3.5.2. Stepwise Activity Based Protein Profiling 
         MDA-MB-231 cells were seeded in five groups of 6 cm petri dishes with 3 ml DMEM high 
glucose culture and incubated at 37 ºC and 5% CO2 until 90% confluency. Each group was treated 
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with fresh medium containing 20 µM competitor or an equal volume of DMSO vehicle for 30 min 
at 37 ºC and 5% CO2, followed by addition of 0.2 µM probe or an equal volume of DMSO. After 
1 h incubation at 37 ºC and 5% CO2, the cells were harvested and washed with cold PBS for 3 
times. The cells were then lysed in 100 µl of lysis buffer 1 (50 mM Hepes pH = 9.0, 100 mM NaCl, 
10% glycerol, 5 mM MgCl2, 1 mM CaCl2, 0.2% NP40, 1x protease inhibitor) using ultrasound 
sonication. The supernatant of each group was collected after centrifugation at 21,100 g and 4 ºC 
for 10 min, and the protein concentration was quantified with a BCA kit. 10% SDS was then added 
into protein solution to make a final SDS concentration of 0.4%, and the solution was incubated at 
95 ºC for 5 min. 1 µl TECP (100 mM stock solution in H2O) was mixed with 1 µl TBTA (10 mM 
stock solution in a 4:1 ratio of t-butanol and DMSO), 1 µl CuSO4 (100 mM stock solution in H2O), 
and 1 µl rhodamine-azide (1 mM stock solution in DMSO). The mixed solution was added into 
the previously prepared protein solution containing 0.25 mg protein. The total volume was adjusted 
to 100 µl with the lysis buffer 1 to make a final protein concentration of 2.5 mg/ml, and the click 
reaction was performed at room temperature for 1.5 h. Proteins in 15 µl of the reactant were 
fractionated by an SDS-PAGE gel. The protein gel was scanned with a typhoon scanner 
(Typhoon™ FLA 9500) at 532 nm excitation with 700 mV gain setting and then stained with 
Coomassie blue. 
3.5.3. Biotin Affinity Pulldown  
3.5.3.1. Live Cell-based Pulldown  
         According to the experimental needs, MDA-MB-231 cells were seeded into 3-7 groups of 
15-cm tissueculture dishes and incubated at 37 ºC and 5% CO2 until 90% confluency. Each group 
was treated with fresh medium containing a competitor or an equal volume of DMSO vehicle for 
30 min at 37 ºC and 5% CO2, followed by addition of a probe or an equal volume of DMSO. After 
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1 h incubation at 37 ºC and 5% CO2, the cells were harvested and washed with cold PBS for 3 
times and lysed with the lysis buffer 2 (50 mM Tris pH=7.4, 150 mM NaCl, 1% NP40, 0.25% 
sodium deoxycholate, 10 mM NaF, 10 mM β-glycerophosphate, and 1 mM Na3VO4). The 
supernatant of each group was collected after centrifugation at 4 ºC and 21,100 g for 10 min, and 
the protein concentration was quantified with the BCA kit. After adjusting protein concentration 
with lysis buffer 2, each protein solution with equal amount of total protein in the same volume 
was incubated with 20 µl of washed streptavidin bead at 4 ºC for 2 h with rotation. After incubation, 
the beads were washed with washing buffer (50 mM Tris pH=7.4, 150mM NaCl, 1% NP40, 0.25% 
Sodium deoxycholate, 10 mM NaF, 10 mM β-glycerophosphate, and 1 mM Na3VO4) for 3 
times and boiled at 95ºC for 5 min in 2x sample buffer (125 mM Tris-HCl PH=6.8, 20% Glycerol, 
2% SDS, 2% β-mercaptoethanol and 0.02% Bromophenol blue). After centrifugation at 21,100 g 
and 4 ºC for 1 min, the cleared eluted proteins were divided into two parts. One part was 
fractionated by a 12% SDS PAGE and visualized by silver staining. The other part was analyzed 
by Western blotting, in which proteins on the nitrocellulose membrane were visualized by either 
fluorescently labeled streptavidin or an anti-Sec61α antibody.  
3.5.3.2. Cell Lysate-based Pulldown  
         MDA-MB-231 cells from seven 15-cm tissue culture dishes were harvested and washed with 
PBS for 3 times and lysed in buffer 2 using ultrasound sonication. The supernatant of each group 
was collected after centrifugation at 21,100 g and 4 ºC for 10 min, and the protein concentration 
was quantified with the BCA kit and adjusted to be between 3.5–4 mg/mL with lysis buffer 2. 
Next, the cell lysate was equally divided into 7 fractions, 1 ml/each. Each fraction was treated with 
either a competitor or an equal volume of DMSO vehicle for 30 min at 4 ºC, followed by the 
addition of a probe or an equal volume of DMSO. All the samples were then incubated at 4 ºC for 
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1 h. After incubation, 20 µl of streptavidin washed bead was added to each sample followed by 2 
h incubation at 4 ºC with rotation. The remaining procedures were the same as the live cell-based 
pulldown (see above).  
3.5.3.3. ER Microsome-based Pulldown  
         1 ul of Ipomoeassin F (2 mM stock concentration) or DMSO vehicle was added to 198.6 ul 
ER microsome suspension in one of the three Eppendorf tubes to produce a final ipomoeassin F 
concentration of 10 µM and two blank tubes. The resulting mixtures were incubated at 4 ºC for 30 
min, followed by addition of 0.2 µM probe (final concentration) to two tubes or an equal volume 
of DMSO to a blank tube. After 1 h incubation at 4 ºC, 10% DDM (n-dodecyl-ß-D-maltoside) was 
added to each tube to give the final concentration of 1%, and the mixtures were further incubated 
at 4 ºC for another 1 h. The supernatant of each group was collected after centrifugation at 4 ºC 
and 21,100 g for 10 min. 20 µl of washed streptavidin beads was added to each sample followed 
by 2 h incubation at 4 ºC with rotation. After washing with washing buffer (50 mM Tris pH=7.4, 
and 150 mM NaCl) for 3 times, the bound proteins were eluted by were boiling the beads in 20 µl 
of 2x sample buffer at 95 ºC for 5 min. The eluted proteins were analyzed by SDS-PAGE or 
Western blotting as described above. 
3.5.4. Mass Spectrometry (MS) Analysis and MS Data Processing 
         In the pulldown, the bound proteins were eluted via boiling the high capacity streptavidin 
agarose beads in 1x sample buffer. The eluted proteins were fractionated with a 12% SDS-PAGE 
and the fractionated proteins were visualized by blue silver staining.33 The 40 kDa protein band 
from the probe 3.3-enriched sample and the corresponding regions of the gel for the negative 
control and the ipomoeassin F competition sample were cut, in-gel digested, the resulting peptides 
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were analyzed by an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific), and the 
MS/MS spectra were searched against a composite target-decoy UniProtkB human protein 
database (2018_02, 20317 entries) using Mascot (Matrix Science, London, UK; version 2.5.1) as 
described previously. 34-35 The parameters for database searching were as follows: MS tolerance 
of 3.0 ppm and MS/MS tolerance of 0.5 Da; tryptic enzyme specificity with a maximum of 2 
missed cleavages; fixed modification, carbamidomethyl of cysteine; and variable modifications, 
oxidation of methionine and acetylation of the N-terminus. Search results were further processed 
by Scaffold software (version 4.8.6; Proteome Software, Portland, OR) for viewing protein and 
peptide identification information. In the Scaffold analysis, peptide identifications were accepted 
if they could achieve a false discovery rate (FDR) of <1.0% by the Scaffold Local FDR algorithm. 
Protein identifications were accepted if they could achieve an FDR of <1.0% and contained at least 
2 identified peptides. Total spectral counts were exported from Scaffold and used to represent 
relative protein abundance from different samples based on the positive, linear correlation between 
spectral count and the abundance of a protein in complex samples.36-38 Contaminant proteins such 
as keratins were discarded. For reliable representation of protein abundance, proteins identified 
with <4 spectra in the probe 3.3 - enriched sample were discarded.37 
3.5.5. Cell Imaging 
         MDA-MB-231 cells were seeded on fibronectin-coated coverslips at 70% confluency in a 
48-well plate and cultured at 37 ºC and 5% CO2. After 24 h, culture medium was replaced with 
fresh medium containing a 20 µM competitor or an equal volume of DMSO vehicle for 30 min at 
37 ºC and 5% CO2, followed by addition of 0.2 µM (final concentration) fluorescent probe 3.7. 
After 1 h incubation, the coverslips were mounted onto a glass slide with a mounting medium with 
or without 0.5 µg/ml DAPI. The fluorescent images were acquired with a confocal microscope 
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(Leica TCS SP5) using 405 nm excitation and 562 nm excitation. For the ER co-localization 
studies, 1uM ER-Tracker™ Blue-White DPX was added to the medium after 1 h incubation with 
probe 3.7. After 5 min incubation, the coverslips were mounted onto a glass slide and the images 
were acquired as described above. 
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3.5.6. Figures and Tables  
3.5.6.1. Cell Cytotoxicity Assay 
 
Figure S 1. Cytotoxicity in MDA-MB-231: Cell viability curves of analogues 3.1, 3.2, 3.3, 3.7 
and ipomoeassin F (72 h incubation).  
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3.5.6.2. Stepwise Activity Based Protein Profiling  
 
A.                                                                     B. 
 
Figure S 2. Click reaction performed after incubating cells with competitor and its corresponding 
alkyne probe. (A) Fluorescent image by a Typhoon scanner. (B) Coomassie Blue stain of the gel. 
(The arrow indicates a positive result for probe X, where a protein band appeared in lane 4 but was 
absent in lanes 1 and 5.)  
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3.5.6.3. Biotin Affinity Pulldown  
 
A.                                                                        B.  
                  
C. 
 
Figure S 3. Biotin affinity pulldown with probes 3.2 and 3.3. Cells were incubated with 
ipomoeassin F and probes, then lysed and subjected to biotin affinity pulldown with streptavidin 
beads. (A) SDS-PAGE and silver staining analysis of pulldown samples from live cells. (B) SDS-
PAGE analysis of pulldown samples from live cells using fluorescently labeled streptavidin. (C) 
SDS-PAGE and silver staining analysis of pulldown samples from cell lysates. Arrows indicate 
the ~40 kDa position. 
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A.                                                   B.                                            C.  
     
Figure S 4. Biotin affinity pulldown with probe 3.3 or 3.5 in the presence of the competitor 
ipomoeassin F or 3.6. (A) Pulldown experiment with 10 nM 3.3 and 50 nM ipomoeassin F. (B) 
Pulldown experiments with either 20 nM 3.3 and 1 μM 3.6 or 500 nM 3.5 without competition. 
Arrows indicate the ~40 kDa position. (C) Pulldown experiment with 5nM and 10nM 3.3.  
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3.5.6.4. Cell Imaging           
A.  
 
                3.7, 0.2µM                                        DAPI                                          Merged  
B． 
 
3.7 (0.2 μM) + Ipom-F (20 μM)                        DAPI                                         Merged 
C． 
 
    3.7 (0.2 μM) + 3.6 (20 μM)                           DAPI                                         Merged 
Figure S 5. Live cell imaging-based competition experiments. (A) Cells were treated with 1 μM 
3.7. (B) Cells were treated with ipomoeassin F (100-fold) and 3.7; (C) Cells were treated with 3.6 
(100-fold) and 3.7. 
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3.5.6.5. Pulldown in ER Microsomes.   
 
 A.                                                                              B.  
                                 
Figure S 6. Biotin affinity pulldown with probe 3.3 in ER microsomes. (A) The proteins were 
visualized by silver staining. The arrow indicates the positive result. (B) The proteins were 
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41 kDa 50 41 53 0.77 
Actin, 
cytoplasmic 1 










ECI2_HUMAN 44 kDa 34 36 51 0.71 
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ROA3_HUMAN 40 kDa 35 24 47 0.51 
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MCCB_HUMAN 61 kDa 36 23 37 0.62 
DnaJ homolog 
subfamily 
B member 11 



















PCBP2_HUMAN 39 kDa 23 20 34 0.59 
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45 kDa 19 18 21 0.86 




1A02_HUMAN 41 kDa 8 8 16 0.5 
Mevalonate 
kinase 




BUB3_HUMAN 37 kDa 8 8 15 0.53 
Nucleolar protein 
7 
NOL7_HUMAN 29 kDa 9 8 10 0.8 
Nucleolysin 
TIAR 
TIAR_HUMAN 42 kDa 9 8 13 0.62 
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KTI12_HUMAN 39 kDa 4 8 12 0.67 
Protein SGT1 
homolog 





























49 kDa 8 7 9 0.78 
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TCPD_HUMAN 58 kDa 14 7 13 0.54 
tRNA 
methyltransferase 
10 homolog C 
TM10C_HUMA
N 




RL40_HUMAN 15 kDa 7 7 12 0.58 
V-type proton 
ATPase 
subunit C 1 
VATC1_HUMA
N 
44 kDa 10 7 15 0.47 
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CSN4_HUMAN 46 kDa 7 6 9 0.67 
Eukaryotic 
translation 
initiation factor 3 
subunit 
H 
EIF3H_HUMAN 40 kDa 6 6 17 0.35 
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HEMH_HUMAN 48 kDa 9 6 13 0.46 























40 kDa 6 6 13 0.46 
Nucleolin NUCL_HUMAN 77 kDa 5 6 6 1 
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47 kDa 4 6 11 0.55 
SUMO-activating 
enzyme subunit 1 
SAE1_HUMAN 38 kDa 11 6 12 0.5 
Ubiquitin-
conjugating 
enzyme E2 Z 
UBE2Z_HUMA
N 




103 kDa 3 5 8 0.63 
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42 kDa 2 5 5 1 
DnaJ homolog 
subfamily 
B member 2 














HSP7C_HUMAN 71 kDa 14 5 19 0.26 
Hsp70-binding 
protein 1 
HPBP1_HUMAN 39 kDa 6 5 8 0.63 
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46 kDa 5 5 10 0.5 
79 






























RFC2_HUMAN 39 kDa 4 5 25 0.2 
RNA 3'-terminal 
phosphate cyclase 






88 kDa 3 5 4 1.25 
Serpin B9 SPB9_HUMAN 42 kDa 11 5 9 0.56 
Twinfilin-2 TWF2_HUMAN 40 kDa 10 5 10 0.5 
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AIFM2_HUMAN 41 kDa 5 4 13 0.31 















41 kDa 16 4 13 0.31 
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40 kDa 6 4 9 0.44 
Desmocollin-1 DSC1_HUMAN 100 kDa 0 4 0 #DIV/0! 
Filamin-A FLNA_HUMAN 281 kDa 7 4 8 0.5 
Flap 
endonuclease 1 















42 kDa 1 4 11 0.36 





70 kDa 6 4 7 0.57 
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HLAE_HUMAN 40 kDa 5 4 4 1 















98 kDa 4 4 8 0.5 
Monocarboxylate 
transporter 4 






42 kDa 3 4 5 0.8 




PHC2_HUMAN 91 kDa 4 4 4 1 
RelA-associated 
inhibitor 
IASPP_HUMAN 89 kDa 1 4 7 0.57 
Serum albumin ALBU_HUMAN 69 kDa 4 4 4 1 
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 CHAPTER 4. FUTURE PROJECT: APPLICATION FOR HIGH-THROUGHPUT 
SCREENING 
     As early as 1990s, high-throughput screening (HTS) of synthetic chemistry libraries against 
various potential therapeutic targets has been applied into pharmaceutic industry.1 For recent 
decades, a significant number of natural products were isolated and characterized with the help of 
bioactivity screening.2 Nowadays, HTS is considered as one of the most key tools in drug 
discovery within the pharmaceutical industry. With the employment of HTS, tens of thousands of 
compounds can be tested in a week to identify the specific mechanisms of different compounds.3    
     However, there is still a large numbers of potential interesting compounds that may be missed 
due the limit detecting sensitivity and screening throughput efficacy.  With the application of new 
techniques and advances in data management, screening sensitivity has greatly improved. Mass 
spectrometry (MS)-based metabolomic profiling is one of those newly developed method. Even 
though this technique is acknowledged as a very sensitive screening approach, it is not easy to 
have it well established in practical throughput screening. Therefore, people are continuously 
looking for high-throughput strategies with ‘low-tech’ but robust output.  
         Sec61, a complex consisted of subunit α, β and γ, constitutes a heterotrimer.4 Multiple 
heterotrimers cluster together to build up a transmembrane aqueous pore channel,5-7 which enables 
of newly synthesized secretory proteins translocation and helps with membrane protein integration 
as well.4,8 As discussed in Chapter 3, ipomoeassin F specifically binds Sec61α leading to its single 
digital nanomolar cytotoxicity IC50 value. This non-covalent binding or reversible covalent weak 
binding between ipomoeassin F probes and Sec61α can be outcompeted by adequate amounts of 
ipomoeasin F since they bind the same target protein. In future project, I will be trying to make the 
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competition easily monitorable with relatively small amounts of material and time, so that it could 
be used as a potential high throughput screening for Sec61α binding compound.   
4.1.Fluorescent probe based HTS study 
         Fluorescent probes have been frequently used for exploring many kinds of bio-activities by 
taking advantage of their indispensable sensitivity and easily accessibility. They could be easily 
traceable at very low quantity, sensitive to ionic strength, PH, viscosity, temperature and 
hydrophobicity.9 Moreover, the fluorescent probes can even present subcellular constitution by 
specific binding to regional specific molecules like DNA, proteins or lipids within organelles.          
4.1.1. Mechanism for fluorescent probe based HTS research 
         Probe 4.1(Figure 4.1) was shown to be an active compound with strong emission signal when 
achieved with the proper excitation wavelength and to maintain favorable stability under 
reasonable continuous excitation.   
Figure 4. 1. Ipomoeassin F analogues 4.1, 4.2. 
         The fluorescent intensity variation reflects probe - target protein complex binding and 
dissociation dynamics. As a result, ipomoeassin F that possesses strong potency and same target 
would perfectly compete probe 4.1 off the target protein binding site, therefore lessens the 
detectable fluorescent intensity (Figure 4.2B); while inactive analogue 4.2 that has no common 
binding site could not push 4.1 out of the protein binding pocket therefore causes no signal 
disturbance (Figure 4.2C). If the same competition was performed on an unknown compound, 
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detectable numerical fluorescent intensity would be a convenient and accurate indicator for 







Figure 4. 2. Live cell imaging-based competition experiments. (A) Cells were treated with 0.2 μM 
4.1. (B) Cells were treated with 20 μM ipomoeassin F and 0.2 μM 4.1; (C) Cells were treated with 
20 μM 4.2 and 0.2 μM 4.1. 
4.1, 0.2µM 
4.1 (0.2µM) + Ipom-F (20 µM) 
4.1 (0.2µM) + 4.2 (20 µM) 
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         Due to the complicated synthesis of homemade positive control ipomoeassin F and negative 
control 4.2, minimizing their required amount during the screening is critical to the feasibility as a 
potential HTS approach. Since HTS may be performed on tens of thousands of compounds, 
optimized time for the whole process is another critical factor that adds weigh to its potential 
availability for realistic application. In this project, I use probe 4.1 fluorescent signal intensity as 
an indicator, and ipomoeassin F and probe 4.2 are recruited as positive control and negative control 
respectively. The goal is to figure out the optimized efficacy on breast cancer cell line MDA-MB-
231 so that it could be possibly used as an HTS for compounds that target Sec61α. 
4.1.2. Optimal work concentration exploration for cell imaging 
         Work concentration of probe 4.1 is directly related to the corresponding competition controls, 
so the minimum amount for relative acceptable clear image is an ideal expected work concentration. 
Since the IC50 value of 4.1 is 253.4nM against MDA-MB-231, 500nM was set to be the highest 















Figure 4. 3. Live cell imaging from 4.1 incubation at different concentration. (A) Cells were 
treated with 25nM 4.1; (B) Cells were treated with 50nM 4.1; (C) Cells were treated with 100nM 
4.1; (D) Cells were treated with 200nM 4.1; (E) Cells were treated with 500nM 4.1. 
         According to the image collected (Figure 4.3), when cells are treated with concentration 
below 100nM, cell image become clearer as we increase the work concentration; as the work 
concentration increased above 100nM, cell morphology is well detected, and signal intensity 
increase at very limited amount. As a result, 100nM is selected to be the best work concentration. 
4.1.3. Optimal treatment time exploration for cell imaging 
         As a potential HTS test, consumption of positive control ipomoeassin F and negative control 
4.2 is one of the biggest concerns, but time cost is also a critical unignorable factor. In order to 
push up the efficiency for competition test, we tried a serious of time to treat cells with probe 4.1 




















Figure 4. 4. Live cell imaging from 4.1 100nM treatment at different time incubation: (A) Cells 
were incubated for 5min; (B) Cells were incubated for 15min; (C) Cells were incubated for 30min; 
(D) Cells were incubated for 45min; (E) Cells were incubated for 60min; (F) Cells were incubated 
for 2h; (G) Cells were incubated for 8h.  
 
         Without doubt, as the treatment time of 4.1 elongated, cell morphology is becoming more 
and more discernable (Figure 4.4). When the time goes beyond 1h, fluorescent intensity become 
stable even given 8h incubation. Therefore, 1h is optimized time when 4.1 labelling and 
disassociation become balanced.  
4.1.4. Optimal fold competition of ipomoeassin F for cell imaging 
         Since the optimized work concentration for probe 4.1 is fixed at 100nM 1h, the best condition 
for competition become the next question. To better understand workable competition condition, 
we tried the competition between ipomoeassin F and probe 4.1 at the fold change ranging from 












Figure 4. 5. Live cell confocal fluorescent microscopy imaging from 1h 4.1 0.1 μM treatment and 
30min ipomoeassin F competition at different competition fold difference: (A) Cells were treated 
with 4.1 without competition; (B) Cells were treated with 4.1 with 25-fold ipomoeassin F 
competition; (C) Cells were treated with 4.1 with 50 fold ipomoeassin F competition; (D) Cells 
were treated with 4.1 with 100 fold ipomoeassin F competition. 
 
         As expected (Figure 4.5), little competitive effect could be detected at 25 and 50-fold 
ipomoeassin F competition. However, when the concentration of ipomoeassin F increased to 100-
fold competition, fluorescent signal was almost competed off. As a result, 100-fold competition is 
figured out to be the ideal condition for the potential HTS.      
4.1.5. Optimal competition time of ipomoeassin F for cell imaging 
         As discussed above, 100-fold of ipomoeassin F completion almost removes fluorescent 
signal form probe 4.1 (Figure 4.5D), but the best competition time is unknown. Since the passive 
penetration of small molecular is very fast, the competition time increases gradually by every 5min, 











Figure 4. 6. Live cell imaging from 1h 4.1 0.1 μM treatment and 100-fold ipomoeassin F 
competition at different competition time: (A) Cells were treated with 4.1 without competition; (B) 
Cells were treated with 5 min competition; (C) Cells were treated with 10 min competition; (D) 
Cells were treated with 15 min competition. 
 
         Probe 4.1 The fluorescent signal perishes fast within 10min competition and keeps a certain 
level ever since then. Compared with 1h incubation to reach peak binding for probe 4.1 at 100nM, 
high dosage (10µM) ipomoeassin F saturates the binding pocket within only 10 min, which 
significantly shorten screen time to 70min.        
4.1.6. Procedure design for fluorescent probe based HTS research 
         Sharing the same target protein Sec61α, competition between ipomoeassin F and probe 4.1 
are employed to isolate other compounds that hit the same target among large quantity of testing 
compounds. Fluorescent intensity variation vividly reflects the binding dynamics, so within proper 
work condition, the set of experiment enable potential application for HTS.  
         After systematic exploration, we found 1h treatment of probe 4.1 at 100nM work 
concentration followed by 10 min 100-fold ipomoeassin F (or testing compound) incubation is a 
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most suitable setting for the screening. As a result, procedure for fluorescent probe based HTS is 
designed as follow: 
Step 1. Seed MDA-MB-231 cells into 96-well plate.  
Step 2. Treat cells with medium containing 10µM positive control ipomoeassin F, negative control 
probe 4.2 and testing compound separately for 10min, followed by incubation with 100nM probe 
4.1 for 1h in each group.  
Step 3. Remove medium from each group and wash thoroughly with PBS for 3 times.  
Step4. Collect fluorescent intensity reading from each group using plate reader at the optimized 
excitation and emission setting. 
Step5. Evaluate the test compound reading with positive control and negative control result.  
4.1.7. Result interpretation  
         Because of the stable and strong fluorescent properties, probe 4.1 is considered as an ideal 
candidate for target protein tracker. Solid result from positive control ipomoeassin F competition, 
negative control 4.2 competition and co-stain with ER tracker point to the conclusion that probe 
4.1 binds to target protein Sec61α and the binding could be competed off by active compound that 
works on the identical binding site.  
         In the screening, fluorescent intensity from each test well represents the amount of 4.1 that 
firmly binds to Sec61α. Test compound that possesses strong affinity with Sec61α may easily 
compete off 4.1 like ipomoeassin F, leading to significant loss of fluorescent signal. Vice versa, 
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low Sec61α affinity compound has little chance to compete 4.1 off, giving rise to large fluorescent 
reading.                
4.2.Biotin probe based HTS study 
4.2.1. Mechanism for biotin probe based HTS research 
         Biotin modified probe 4.3 is proved to have specific binding with ER transmembrane protein 
Sec61α, and its binding can be competed away by ipomoeassin F that target the same site. Like 
the fluorescent probe based HTS study, proper condition and strategies for quantification would 
enable this probe a valuable potential candidate for HTS.  
 
Figure 4. 7. Structure of ipomoeassin F analogues 4.3. 
 
         Rather than generating detectable signal from the probe itself, 4.3 could excite secondary 
signal by biotin affinity strategies. For protein visualization, antibody-based detection approach 
western blot and ELISA are most commonly used due to the high sensitivity and specificity. 
However, western blot is not a first consideration for high throughput screening due to the fussy 
procedure. So, ELISA is applied to develop an easily accessible approach to effectively identify 
Sec61α affinity compounds by biotin probe competition. Due to the limited time and restriction of 
work condition, the following exploration for HTS application is designed for future work and 
lack of supportive experimental data. 
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4.2.2. HTS work condition optimization.  
         The Sec61α affinity compound screening is based on competition with probe 4.3 by using 
active compound ipomoeassin F and negative compound 4.2 as reference. Hence, standardize the 
work condition for competition and binding signal visualization is the key to perform HTS.  
         Firstly, the minimum ER microsome amount required for the screening will be evaluated to 
make sure enough target protein would be detectable in the visualization step. Based on the 
understanding of minimum number of ER microsome needed, the lowest work concentration C1 
of 4.3 for clear and stable visualization will be explored. Next, the optimized 4.3 incubation time 
T1 would be determined. In the following step, optimized competition fold difference F1 and its 
competition time T2 for ipomoeassin F will be figured out. At last, since the commercial available 
anti-biotin antibody coated ELISA is standardized, conjugated antibody work condition in ELISA 
test will be optimized.  
4.2.3. Procedure design for biotin probe based HTS research 
         In this project, our ultimate purpose is to quantitatively visualize the amount of 4.3 - Sec61α 
complex with the help of enzyme conjugated antibody or radioactive antibody. The procedure of 
biotin based HTS is listed as follow:  
Step 1. Prepare sample as following    
            ER microsome is treated with positive control ipomoeassin F, negative control  
            probe 4.2 and testing compound separately at the concentration of C1*F1 for time T2,  
            followed by incubation with probe 4.3 at the concentration of C1 for time T1 in each  
            group. Then after multiple wash was performed in each group, n-dodecyl-ß-D-maltoside 
            (DDM) will be added into each group to disrupt ER membrane structure.  
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Step 2. Add 100µl of sample from each group to anti-biotin polyclonal antibody coated 96 well  
            plate and incubate in room temperature for 2 h.  
Step3. Wash plate thoroughly before adding anti-Sec61α mono clonal secondary enzyme  
            conjugated antibody and incubate in room temperature for 2h. 
Step 4. Wash the plate thoroughly before adding substrate. Then read the plate after 0.5-1h room  
            temperature incubation.    






Figure 4. 8. Work flow of biotin-based HTS. (A) Elisa procedure diagram. (B) Testing result 













4.2.4. Result interpretation  
         In the screening, cells are treated with high dosage ipomoeassin F, probe 4.2 and test 
compound respectively. Positive control ipomoeassin F saturates Sec61α binding site in the high 
concentration incubation, negative control does not consume any Sec61α binding site even in high 
concentration. As a result, in the following incubation step, probe 4.3 is not able to bind Sec61α 
in positive group but can freely bind Sec61α at its maximum capability. In this case, sample from 
positive group contain little 4.3-Sec61α complex, while sample from negative group accumulate 
relatively large amount of 4.3-Sec61α complex. 
         Since biotin is a key function group of 4.3, coating antibody can easily capture 4.3-Sec61α 
in negative group but keeps little such complex in positive group. In the following steps, only 
negative group would successfully bind enzyme conjugated antibody and catalyze substrate to 
produce detectable signals. Therefore, the stronger signal suggests the lower binding affinity 
between test compound and Sec61α, vice versa.  
4.3.Conclusion  
         Sec61α is a critical ER transmembrane protein that play an indispensable role in protein 
translocation. Applying HTS to identify natural product or synthetic compound that work on 
Sec61α would provide abundant resources to develop anti-cancer drugs in medicinal chemistry.        
         Competition between probe 4.1 vs ipomoeassin F and probe 4.3 vs ipomoeassin F are well 
established and based on their common binding protein Sec61α. Stable fluorescent property of 
probe 4.1 enable its further potential application in HTS to search Sec61α high affinity compounds 
by the comparation of ipomoeassin F competition. Albeit a lot of work need to be done, the great 
sensitivity and easy accessibility endow the approach a promising future HTS. Unlike other probes, 
when 4.3 specifically binds Sec61α, the core structure is buried inside the complex, sprouting the 
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biotin group as a sticky end to provide extra binding site for ELISA quantitative visualization. 
Competition from Sec61α high affinity compound is expected to be reflected on the ELISA 
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SUMMARY AND CONCLUSIONS 
         Ipomeassin F is found to be one of promising natural products that would potentially curb 
cancer neoplasia. In order to better understand the property of this newly developed compound, 
we performed systematic SAR study and deep exploration on its MOA by using breast cancer 
cell line MDA-MB-231 and MCF-7 as models.  
         Based on the complicated SAR study, we reveal that lipophilicity is vital to retain potency 
of ipomoeassin F. Hydrophilic moieties in ipomoeassin F not only maintain the conformational 
stability but also work as vessel to efficiently deliver the compound into cells from aqueous 
environment. Impact significance of each group on ipomoeassin F potency is in the order of: D-
Fucp >cinnamate >tiglate >alkene in cinnamate > alkene in tiglate > acetate > 3-OH-
Fucp >cyclic skeleton ≈ ketone. 
         After treating cancer cells, ipomoeassin F would localize in ER and interact with the target 
protein Sec61α by non-covalent binding or weak reversible covalent binding. The binding pocket 
is deep inside the complex, and the firmly binding between ipomoeassin F and Sec61α requires 
membrane environment to sustain stability.  
         By employing ipomoeassin F analogues which share same target Sec61α, potential 
applications for Sec61α affinity compound HTS would be available. The application could be 
either analyzed by fluorescent intensity analysis or biotin-based ELISA signal analysis.  
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